[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 134
1. Muñoz A, Riber C, Trigo P, Castejón F: Hematopoietic neoplasias in horses: myeloproliferative and lymphoproliferative disorders. J Equine Sci; 2009;20(4):59-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic neoplasias in horses: myeloproliferative and lymphoproliferative disorders.
  • Leukemia can be classified according to the affected cells (myeloproliferative or lymphoproliferative disorders), evolution of clinical signs (acute or chronic) and the presence or lack of abnormal cells in peripheral blood (leukemic, subleukemic and aleukemic leukemia).
  • The main myeloproliferative disorders in horses are malignant histiocytosis and myeloid leukemia, the latter being classified as monocytic and myelomonocytic, granulocytic, primary erythrocytosis or polycythemia vera and megakaryocytic leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24833969.001).
  • [ISSN] 1340-3516
  • [Journal-full-title] Journal of equine science
  • [ISO-abbreviation] J Equine Sci
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC4013965
  • [Keywords] NOTNLM ; anemia / blood / clinical pathology / horses / leukemia
  •  go-up   go-down


2. Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR: Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica; 2010 Jul;95(7):1216-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmunity and the risk of myeloproliferative neoplasms.
  • The causes of myeloproliferative neoplasm (MPN) are unknown.
  • We conducted a large population-based study including 11,039 myeloproliferative neoplasm patients and 43,550 matched controls with the aim of assessing the associations between a personal history of a broad span of autoimmune diseases and subsequent risk of myeloproliferative neoplasm.
  • We found a prior history of any autoimmune disease to be associated with a significantly increased risk of myeloproliferative neoplasms (odds ratio (OR)=1.2; 95% confidence interval (CI) 1.0-1.3; P=0.021).
  • Specifically, we found an increased risk of MPNs associated with a prior immune thrombocytopenic purpura (2.9; 1.7-7.2), Crohn's disease (1.8; 1.1-3.0), polymyalgia rheumatica (1.7; 1.2-2.5), giant cell arteritis (5.9; 2.4-14.4), Reiter's syndrome (15.9; 1.8-142) and aplastic anemia (7.8; 3.7-16.7).
  • The risk of myeloproliferative neoplasms associated with prior autoimmune diseases is modest but statistically significant.

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2009 Mar;20(3):574-80 [18765463.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2199-204 [18451307.001]
  • [Cites] Nat Genet. 2009 Apr;41(4):446-9 [19287382.001]
  • [Cites] Nat Genet. 2009 Apr;41(4):455-9 [19287384.001]
  • [Cites] Nat Genet. 2009 Apr;41(4):450-4 [19287385.001]
  • [Cites] Haematologica. 2009 Oct;94(10):1468-9 [19794095.001]
  • [Cites] Br J Cancer. 2009 Mar 10;100(5):822-8 [19259097.001]
  • [Cites] J Rheumatol. 2000 Sep;27(9):2179-84 [10990231.001]
  • [Cites] J Rheumatol. 2002 Oct;29(10):2143-7 [12375324.001]
  • [Cites] Cancer. 1984 Apr 15;53(8):1770-6 [6365308.001]
  • [Cites] Blood. 1990 Dec 1;76(11):2222-8 [2257296.001]
  • [Cites] Blood. 1991 Jul 15;78(2):277-9 [2070065.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1152-7 [8377778.001]
  • [Cites] J Rheumatol. 1993 Aug;20(8):1335-9 [8230015.001]
  • [Cites] Medicine (Baltimore). 2005 Sep;84(5):277-90 [16148728.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):51-60 [16391371.001]
  • [Cites] Arch Pathol Lab Med. 2006 Aug;130(8):1144-50 [16879015.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1377-80 [16675710.001]
  • [Cites] Cell Cycle. 2007 Mar 1;6(5):550-66 [17351342.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4):587-95 [17379069.001]
  • [Cites] Semin Thromb Hemost. 2007 Jun;33(4):313-20 [17525888.001]
  • [Cites] Dis Colon Rectum. 2007 Jun;50(6):839-55 [17308939.001]
  • [Cites] Leukemia. 2008 Jan;22(1):14-22 [17882280.001]
  • [Cites] Nat Genet. 2008 Aug;40(8):955-62 [18587394.001]
  • [CommentIn] Haematologica. 2010 Jul;95(7):1226-7 [20595103.001]
  • (PMID = 20053870.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2895049
  •  go-up   go-down


3. Kim YW, Koo BK, Jeong HW, Yoon MJ, Song R, Shin J, Jeong DC, Kim SH, Kong YY: Defective Notch activation in microenvironment leads to myeloproliferative disease. Blood; 2008 Dec 1;112(12):4628-38
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defective Notch activation in microenvironment leads to myeloproliferative disease.
  • Our 2 independent Mib1 conditional knockout (CKO) mouse lines each developed a myeloproliferative disease (MPD), with gradual accumulations of immature granulocytes.
  • The mutant mice showed hepatosplenomegaly, anemia, granulocytosis, and leukocyte infiltration in multiple organs and finally died at approximately 20 weeks of age.
  • [MeSH-major] Myeloproliferative Disorders / genetics. Receptors, Notch / genetics. Receptors, Notch / metabolism. Ubiquitin-Protein Ligases / genetics

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18818392.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Notch; EC 6.3.2.19 / MIB1 protein, mouse; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


Advertisement
4. Chan G, Kalaitzidis D, Usenko T, Kutok JL, Yang W, Mohi MG, Neel BG: Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood; 2009 Apr 30;113(18):4414-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
  • Expression of Ptpn11(D61Y) in all hematopoietic cells evokes a fatal myeloproliferative disorder (MPD), featuring leukocytosis, anemia, hepatosplenomegaly, and factor-independent colony formation by bone marrow (BM) and spleen cells.

  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - B6.129S6-Ptpn11<tm6Bgn>/Mmjax (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Dec 1;102(12):3938-46 [12907435.001]
  • [Cites] Dev Biol. 2002 Apr 15;244(2):305-18 [11944939.001]
  • [Cites] J Clin Invest. 2004 Feb;113(4):528-38 [14966562.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4243-50 [14982883.001]
  • [Cites] Blood. 2004 Aug 1;104(3):659-66 [15090451.001]
  • [Cites] Nat Med. 2004 Aug;10(8):849-57 [15273746.001]
  • [Cites] Blood. 1974 Mar;43(3):341-50 [4521369.001]
  • [Cites] Blood. 1991 Mar 1;77(5):925-9 [1704804.001]
  • [Cites] Science. 1995 Sep 8;269(5229):1427-9 [7660125.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5860-5 [8650183.001]
  • [Cites] Cell. 1998 Feb 20;92(4):441-50 [9491886.001]
  • [Cites] Structure. 1998 Mar 15;6(3):249-54 [9551546.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):179-91 [15710330.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1937-45 [15522951.001]
  • [Cites] Blood. 2005 May 1;105(9):3737-42 [15644411.001]
  • [Cites] Blood. 2005 Jul 1;106(1):311-7 [15761018.001]
  • [Cites] Cell. 2005 Jul 1;121(7):1109-21 [15989959.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2005;6:45-68 [16124853.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):30984-93 [15987685.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):175-87 [16530702.001]
  • [Cites] Blood. 2006 Sep 15;108(6):2041-4 [16720837.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):23-30 [17227708.001]
  • [Cites] Blood. 2007 Feb 1;109(3):862-7 [17053061.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1687-91 [17090653.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):295-308 [17384584.001]
  • [Cites] Blood. 2007 May 1;109(9):3945-52 [17192389.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5238-41 [17317860.001]
  • [Cites] Cell. 2007 Jun 15;129(6):1081-95 [17574022.001]
  • [Cites] Cell. 2007 Jun 15;129(6):1097-110 [17574023.001]
  • [Cites] J Clin Invest. 2008 Mar;118(3):853-67 [18246201.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):263-70 [18371361.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):311-20 [18394554.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):321-30 [18394555.001]
  • [Cites] Cell Stem Cell. 2008 Apr 10;2(4):380-91 [18397757.001]
  • [Cites] Cancer Metastasis Rev. 2008 Jun;27(2):179-92 [18286234.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1335-42 [18548091.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):335-43 [18835035.001]
  • [Cites] PLoS One. 2008;3(11):e3776 [19020663.001]
  • [Cites] Mol Cell. 2000 Jan;5(1):189-95 [10678181.001]
  • [Cites] J Clin Invest. 2001 Sep;108(5):709-15 [11544276.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):465-8 [11704759.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):597-602 [14699048.001]
  • (PMID = 19179468.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA114945; United States / NHLBI NIH HHS / HL / T32 HL007623; United States / NHLBI NIH HHS / HL / 5T32-HL07623-20
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / STAT5 Transcription Factor; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.1.3.48 / Ptpn11 protein, mouse
  • [Other-IDs] NLM/ PMC2676094
  •  go-up   go-down


5. Jekarl DW, Han SB, Kim M, Lim J, Oh EJ, Kim Y, Kim HJ, Min WS, Han K: JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia. Korean J Hematol; 2010 Mar;45(1):46-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia.
  • This mutation occurs less frequently in acute myeloid leukemia (AML) and other hematologic diseases, such as myelodysplastic syndrome (MDS); myelodysplatic syndrome/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U); and refractory anemia with ring sideroblasts with thrombocytosis (RARS-T).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21120162.001).
  • [ISSN] 2092-9129
  • [Journal-full-title] The Korean journal of hematology
  • [ISO-abbreviation] Korean J Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2983014
  • [Keywords] NOTNLM ; AML / JAK2 V617F / MDS / MDS/MPN-U / RARS-T
  •  go-up   go-down


6. Remacha AF, Nomdedéu JF, Puget G, Estivill C, Sarda MP, Canals C, Aventin A: Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica; 2006 May;91(5):719-20
MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
  • We investigated 19 cases with refractory anemia with ringed sideroblasts (RARS), including three RARS with thrombocytosis (RARS-T).
  • [MeSH-major] Anemia, Refractory / genetics. Anemia, Sideroblastic / genetics. Mutation, Missense. Myelodysplastic Syndromes / classification. Myeloproliferative Disorders / classification. Point Mutation. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins / genetics. Thrombocytosis / genetics

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Myelodysplastic myeloproliferative disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670082.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


7. Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, Sekeres MA, Maciejewski JP: Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood; 2006 Oct 1;108(7):2173-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
  • JAK2 V617F mutation recently was identified as a pathogenic factor in typical chronic myeloproliferative diseases (CMPD).
  • Within this group, most of the patients harboring JAK2 V617F mutation showed features consistent with the provisional MDS/MPD-U entity refractory anemia with ringed sideroblasts and thrombocytosis (RARS-T).

  • Genetic Alliance. consumer health - Anemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Immunol. 2000 Jan-Feb;37(1-2):1-11 [10781830.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1843-4 [16079889.001]
  • [Cites] Gene. 2002 Feb 20;285(1-2):1-24 [12039028.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):557-9 [12688334.001]
  • [Cites] J Clin Invest. 2004 Feb;113(4):619-27 [14966571.001]
  • [Cites] Nature. 1996 Oct 24;383(6602):726-8 [8878484.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:297-317 [15561689.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):547-52 [15607959.001]
  • [Cites] Br J Haematol. 2005 Oct;131(2):208-13 [16197451.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2769-80 [15914562.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3370-3 [16037387.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3377-9 [16081687.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2359-60 [16239910.001]
  • [Cites] Br J Haematol. 2006 Jan;132(2):244-5 [16398659.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1242-3 [16434499.001]
  • [Cites] Leukemia. 2006 Mar;20(3):534-5 [16408096.001]
  • [Cites] Am J Clin Pathol. 2006 Apr;125(4):625-33 [16627272.001]
  • [Cites] Blood. 2006 May 1;107(9):3676-82 [16373657.001]
  • [Cites] Leuk Res. 2005 Apr;29(4):365-70 [15725469.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1207-9 [15860661.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2162-8 [15920007.001]
  • [Cites] Br J Haematol. 2005 Sep;130(6):964-5 [16156866.001]
  • [Cites] Br J Haematol. 2005 Sep;130(6):968 [16156870.001]
  • [Cites] Exp Hematol. 2001 Jun;29(6):694-702 [11378264.001]
  • (PMID = 16741247.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL082983-01; United States / NHLBI NIH HHS / HL / R01 HL73429-01; United States / NCRR NIH HHS / RR / U54 RR019391-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Other-IDs] NLM/ PMC1895556
  •  go-up   go-down


8. Orazi A, Germing U: The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia; 2008 Jul;22(7):1308-19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.
  • The 2001 World Health Organization (WHO)-sponsored classification of hematopoietic tumors has, for the first time, clearly defined a group of rare myeloid neoplasms termed myelodysplastic/myeloproliferative diseases (MDS/MPDs).
  • In the upcoming fourth edition of the WHO fascicle, due out later this year, the term 'MPD' is replaced by 'myeloproliferative neoplasm (MPN)'.
  • [MeSH-major] Myelodysplastic-Myeloproliferative Diseases / classification. Myeloproliferative Disorders / classification
  • [MeSH-minor] Anemia, Refractory / classification. Chromatin / chemistry. Diagnosis, Differential. Humans. Janus Kinase 2 / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / classification. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelomonocytic, Chronic / classification. Leukemia, Myelomonocytic, Chronic / diagnosis. Leukemia, Myelomonocytic, Chronic / genetics. Mutation. Prognosis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480833.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromatin; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 66
  •  go-up   go-down


9. D'Angelo G: Refractory anemia with ringed sideroblasts and chronic myelomonocytic leukemia: myelodysplastic/myeloproliferative disease. Lab Hematol; 2005;11(3):171-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory anemia with ringed sideroblasts and chronic myelomonocytic leukemia: myelodysplastic/myeloproliferative disease.
  • Here is reported the case of an elderly woman that, after surgical intervention, showed an important anemia, leucocytosis and thrombocytopenia.
  • The morphological appearances, both peripheral blood and bone marrow, showed an evident overlapping of myelodysplastic and myeloproliferative picture, characterized from the presence of refractory anemia with ringed sideroblasts (RARS) and chronic myelomonocytic leukemia (CMML).
  • Currently, the World Health Organization (WHO) has given an arrangement to the hematological picture with myelodysplastic and myeloproliferative morphological appearances, including this pathology in a new category: myelodysplastic/myeloproliferative diseases (MDS/MPD).
  • [MeSH-major] Anemia, Refractory / pathology. Anemia, Sideroblastic / metabolism. Bone Marrow Cells / pathology. Leukemia, Myelomonocytic, Chronic / metabolism


10. Barosi G, Magrini U, Gale RP: Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis? Leuk Res; 2010 Sep;34(9):1119-20
MedlinePlus Health Information. consumer health - Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?
  • [MeSH-major] Anemia / immunology. Autoimmunity. Myeloproliferative Disorders / immunology. Primary Myelofibrosis / immunology

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20538336.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Anuk D, Tarcan A, Alioglu B, Avci Z, Haberal N, Ozyurek E, Ozbek N: Hydrops fetalis in a neonate with down syndrome, transient myeloproliferative disorder and hepatic fibrosis. Fetal Pediatr Pathol; 2007 Sep-Dec;26(5-6):223-8
MedlinePlus Health Information. consumer health - Down Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydrops fetalis in a neonate with down syndrome, transient myeloproliferative disorder and hepatic fibrosis.
  • Transient myeloproliferative disorder is a self limiting disorder characterized by leukocytosis with the presence of megakaryoblasts in the peripheral blood and bone marrow, anemia, thrombocytopenia, and organomegaly.
  • Hepatic fibrosis is seen in the severe form of transient myeloproliferative disorder with Down syndrome that is characterized by diffuse intralobular sinusoidal fibrosis and extramedullary hematopoesis.
  • We describe a patient with hydrops fetalis, Down syndrome, and transient myeloproliferative disorder.
  • We suggest that patients with the severe form of transient myeloproliferative disorder should be examined for hepatic fibrosis.
  • [MeSH-major] Down Syndrome / complications. Hydrops Fetalis / etiology. Liver Cirrhosis / etiology. Myeloproliferative Disorders / complications


12. Millecker L, Lennon PA, Verstovsek S, Barkoh B, Galbincea J, Hu P, Chen SS, Jones D: Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations. Cancer Genet Cytogenet; 2010 Feb;197(1):1-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations.
  • Chronic myeloproliferative neoplasms (MPN), including essential thrombocythemia (ET) and primary myelofibrosis (PMF), result from interactions between initiating growth factor mutations and secondary genomic changes.
  • Median mutation levels in pretreatment ET samples were significantly higher for MPL-mutated cases (60%) than for JAK2-mutated cases (24%; P=0.01), as was presentation with anemia.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20113830.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / Receptors, Thrombopoietin; 143641-95-6 / MPL protein, human; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


13. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A: The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer; 2007 Jan 1;109(1):68-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.
  • BACKGROUND: Few objective data exist on the burden of fatigue and other constitutional symptoms in patients with myeloproliferative disorders (MPD).
  • As expected, the presence of myelofibrosis, anemia, splenomegaly, or other features associated with advanced disease favored a higher degree of fatigue.
  • [MeSH-major] Fatigue. Myeloproliferative Disorders / psychology. Polycythemia Vera / physiopathology. Quality of Life

  • MedlinePlus Health Information. consumer health - Fatigue.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 17123268.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA96780
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


14. Gibson SE, Schade AE, Szpurka H, Bak B, Maciejewski JP, Hsi ED: Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F. Hum Pathol; 2008 Jul;39(7):1111-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F.
  • Abnormal nuclear megakaryocytic staining for phospho-STAT5 (pSTAT5) correlates with JAK2 V617F mutational status in non-chronic myelogenous leukemia chronic myeloproliferative disorders.
  • However, a proportion of wild-type JAK2 non-chronic myelogenous leukemia chronic myeloproliferative disorders cases also demonstrate this abnormal pSTAT5 expression pattern.
  • We report a patient with a JAK2 V617F-negative myeloproliferative/myelodysplastic syndrome who had abnormal megakaryocytic pSTAT5 expression and a MPL W515L mutation.
  • The patient was a 71-year-old man with anemia and thrombocythemia on laboratory examination.
  • Bone marrow biopsy revealed hypercellular marrow with features consistent with myeloproliferative/myelodysplastic syndrome.
  • [MeSH-major] Janus Kinase 2 / genetics. Myelodysplastic-Myeloproliferative Diseases / metabolism. Point Mutation. Receptors, Thrombopoietin / genetics. STAT5 Transcription Factor / metabolism

  • Genetic Alliance. consumer health - Chronic Myeloproliferative Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18479730.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Thrombopoietin; 0 / STAT5 Transcription Factor; 143641-95-6 / MPL protein, human; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


15. Grigg A: Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease. Intern Med J; 2007 Mar;37(3):190-2
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease.
  • Hydroxyurea (HU) is not infrequently used in patients with sickle cell disease and myeloproliferative disorders.
  • [MeSH-major] Anemia, Sickle Cell / drug therapy. Antisickling Agents / adverse effects. Hydroxyurea / adverse effects. Myeloproliferative Disorders / drug therapy. Nucleic Acid Synthesis Inhibitors / adverse effects. Spermatozoa / drug effects

  • Genetic Alliance. consumer health - Sickle Cell Disease.
  • MedlinePlus Health Information. consumer health - Sickle Cell Anemia.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17316339.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antisickling Agents; 0 / Nucleic Acid Synthesis Inhibitors; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


16. Fukuhara T, Kakinoki Y: [Clinical features of a new category, myelodysplastic/myeloproliferative diseases, defined by WHO classification]. Rinsho Byori; 2006 Mar;54(3):243-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of a new category, myelodysplastic/myeloproliferative diseases, defined by WHO classification].
  • The WHO classification published in 2001 defined a new category of hematological disease, myelodysplastic/myeloproliferative diseases (MDS/MPD), that have both myelodysplasia and myeloproliferation at the time of initial presentation.
  • There were four MDS/MPD cases with a history of preceding hematological diseases, such as aplastic anemia, MDS or malignant lymphoma.
  • [MeSH-major] Myelodysplastic Syndromes / classification. Myeloproliferative Disorders / classification. World Health Organization

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16637572.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Advanced Glycosylation End Product-Specific Receptor; 0 / Receptors, Immunologic
  •  go-up   go-down


17. Hall J, Foucar K: Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders. Int J Lab Hematol; 2010 Dec;32(6 Pt 2):559-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
  • INTRODUCTION: The 2008 World Health Organization classification of myeloid neoplasms includes the diagnostic category, myelodysplastic/myeloproliferative neoplasms (MDS/MPN), which encompasses those rare clonal myeloid proliferations that at initial presentation, show overlapping myeloproliferative and myelodysplastic features, making classification as either a myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) problematic.
  • There are four main subcategories, chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia, BCR-ABL1-negative (aCML), juvenile myelomonocytic leukemia (JMML), and myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U), which also includes the provisional entity, refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T).
  • CONCLUSION: The most appropriate classification of myeloid neoplasms presenting with hybrid myelodysplastic/myeloproliferative features requires a comprehensive clinical and laboratory assessment with careful integration of the morphological, immunophenotypic, genetic, and clinical characteristics.
  • [MeSH-major] Myelodysplastic Syndromes / diagnosis. Myeloproliferative Disorders / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia, Refractory, with Excess of Blasts / diagnosis. Bone Marrow / pathology. Diagnosis, Differential. Erythrocytes / pathology. Female. Flow Cytometry. Granulocytes / pathology. Humans. Immunohistochemistry. Leukemia, Myeloid / diagnosis. Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / diagnosis. Leukemia, Myelomonocytic, Chronic / diagnosis. Leukemia, Myelomonocytic, Juvenile / diagnosis. Male. Megakaryocytes / pathology. Neutrophils / pathology. Proto-Oncogene Proteins c-abl / analysis. Proto-Oncogene Proteins c-bcr / analysis. Thrombocytosis / diagnosis

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20670271.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / Proto-Oncogene Proteins c-abl; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr
  •  go-up   go-down


18. Cadieux C, Fournier S, Peterson AC, Bédard C, Bedell BJ, Nepveu A: Transgenic mice expressing the p75 CCAAT-displacement protein/Cut homeobox isoform develop a myeloproliferative disease-like myeloid leukemia. Cancer Res; 2006 Oct 1;66(19):9492-501
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transgenic mice expressing the p75 CCAAT-displacement protein/Cut homeobox isoform develop a myeloproliferative disease-like myeloid leukemia.
  • The increase in neutrophils correlated with signs of anemia and thrombocytopenia, whereas there was no indication of a reactive process.
  • Therefore, p75 CDP/Cux transgenic mice displayed heightened susceptibility to a disease defined as a myeloproliferative disease-like myeloid leukemia.
  • [MeSH-major] Homeodomain Proteins / physiology. Leukemia, Myeloid / genetics. Myeloproliferative Disorders / genetics. Nuclear Proteins / physiology. Repressor Proteins / physiology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018605.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CUX1 protein, human; 0 / Homeodomain Proteins; 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / Recombinant Fusion Proteins; 0 / Repressor Proteins
  •  go-up   go-down


19. Andrikovics H, Meggyesi N, Szilvasi A, Tamaska J, Halm G, Lueff S, Nahajevszky S, Egyed M, Varkonyi J, Mikala G, Sipos A, Kalasz L, Masszi T, Tordai A: HFE C282Y mutation as a genetic modifier influencing disease susceptibility for chronic myeloproliferative disease. Cancer Epidemiol Biomarkers Prev; 2009 Mar;18(3):929-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HFE C282Y mutation as a genetic modifier influencing disease susceptibility for chronic myeloproliferative disease.
  • Few reports addressed this issue with relation to chronic myeloproliferative disorders (CMPD).
  • Because chronic iron deficiency or latent anemia may trigger disease susceptibility for CMPD, HFE C282Y positivity may be a genetic factor influencing this effect.
  • [MeSH-major] Genetic Predisposition to Disease. Histocompatibility Antigens Class I / genetics. Membrane Proteins / genetics. Mutation. Myeloproliferative Disorders / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258483.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HFE protein, human; 0 / Histocompatibility Antigens Class I; 0 / Membrane Proteins; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


20. Thiele J, Kvasnicka HM, Diehl V: Bone marrow CD34+ progenitor cells in Philadelphia chromosome-negative chronic myeloproliferative disorders--a clinicopathological study on 575 patients. Leuk Lymphoma; 2005 May;46(5):709-15
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow CD34+ progenitor cells in Philadelphia chromosome-negative chronic myeloproliferative disorders--a clinicopathological study on 575 patients.
  • Contrasting the circulating CD34+ hematopoietic progenitor cells (HPCs) in chronic myeloproliferative disorders (CMPDs), scant knowledge is available regarding their quantity in the bone marrow (BM).
  • A significant association between the quantity of HPCs and the development of myelofibrosis, splenomegaly, and anemia as well as an increase in peripheral blasts was recognizable in CIMF.
  • [MeSH-major] Antigens, CD34 / metabolism. Bone Marrow Cells / pathology. Hematopoietic Stem Cells / pathology. Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / pathology. Myeloproliferative Disorders / pathology

  • Genetic Alliance. consumer health - Chronic Myeloproliferative Disorders.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019508.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


21. Boveri E, Passamonti F, Rumi E, Pietra D, Elena C, Arcaini L, Pascutto C, Castello A, Cazzola M, Magrini U, Lazzarino M: Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. Br J Haematol; 2008 Jan;140(2):162-8
Genetic Alliance. consumer health - Chronic Myeloproliferative Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
  • Philadelphia-negative chronic myeloproliferative disorders (CMD) include polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF).
  • [MeSH-major] Bone Marrow / blood supply. Myeloproliferative Disorders / pathology. Neovascularization, Pathologic / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anemia / etiology. Chronic Disease. Female. Humans. Janus Kinase 2 / genetics. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Mutation. Polycythemia Vera / genetics. Polycythemia Vera / pathology. Primary Myelofibrosis / genetics. Primary Myelofibrosis / pathology. Thrombocythemia, Essential / genetics. Thrombocythemia, Essential / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18028479.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


22. Yamamoto K, Katayama Y, Shimoyama M, Matsui T: Therapy-related myelodysplastic/myeloproliferative neoplasms with del(5q) and t(1;11)(p32;q23) lacking MLL rearrangement. Intern Med; 2010;49(11):1031-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related myelodysplastic/myeloproliferative neoplasms with del(5q) and t(1;11)(p32;q23) lacking MLL rearrangement.
  • A 69-year-old man was admitted because of macrocytic anemia and peripheral monocytosis: hemoglobin 75 g/L and white blood cells 16.0x10(9) /L with 22% monocytes.
  • These findings indicated a diagnosis of therapy-related myelodysplastic/myeloproliferative neoplasms (t-MDS/MPN).

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20519822.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 17
  •  go-up   go-down


23. Shaw GR: Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol; 2005 Oct;131(2):180-4
MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults.
  • [MeSH-major] Anemia, Sideroblastic / classification. Myelodysplastic Syndromes / classification. Myeloproliferative Disorders / classification. Thrombocytosis / classification

  • Genetic Alliance. consumer health - Myelodysplastic myeloproliferative disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2006 Aug;134(3):340; author reply 340-1 [16787502.001]
  • (PMID = 16197447.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Starý J, Locatelli F, Niemeyer CM, European Working Group on Myelodysplastic Syndrome (EWOG-MDS) and Pediatric Diseases Working Party of the EBMT: Stem cell transplantation for aplastic anemia and myelodysplastic syndrome. Bone Marrow Transplant; 2005 Mar;35 Suppl 1:S13-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell transplantation for aplastic anemia and myelodysplastic syndrome.
  • SUMMARY: Stem cell transplantation (SCT) from a histocompatible sibling is treatment of choice for severe aplastic anemia.
  • Juvenile myelomonocytic leukemia (JMML) shares both myelodysplastic and myeloproliferative features.
  • [MeSH-major] Anemia, Aplastic / therapy. Leukemia, Myeloid / therapy. Myelodysplastic Syndromes / therapy. Stem Cell Transplantation


25. Symeonidis A, Kouraklis-Symeonidis A, Psiroyiannis A, Leotsinidis M, Kyriazopoulou V, Vassilakos P, Vagenakis A, Zoumbos N: Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus. Ann Hematol; 2006 Feb;85(2):79-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus.
  • We investigated erythropoietin (Epo) response in a cohort of diabetic patients with various types of anemia to approach the pathogenesis of some cases of "unexplained" anemia encountered among diabetics.
  • Serum Epo levels were determined totally in 747 evaluable subjects with normal renal and hepatic function, of whom 694 had anemia.
  • Diabetic and nondiabetic subjects were uniformly balanced in relation to their demographic features and were categorized according to the etiology of their anemia.
  • Diabetic patients had significantly lower serum Epo levels as compared to nondiabetics (36.5+/-61 vs 69.4+/-191 IU/ml, p<0.0001), and this was true for all etiologic groups of anemia with the exception of patients with myeloproliferative disorders and those with megaloblastic anemia.
  • The natural logarithmic (ln)-EpoxHb component was used as an index of response to anemia and was found to be significantly decreased in almost all subgroups of diabetic patients.
  • Inappropriately low serum Epo level is a uniform feature in patients with type II diabetes mellitus and may represent a constitutive blunted response to anemia or an altered metabolic rate of Epo, probably as a result of abnormal glycosylation of the cytokine.
  • [MeSH-major] Anemia / complications. Anemia / drug therapy. Diabetes Mellitus, Type 2 / complications. Diabetes Mellitus, Type 2 / drug therapy. Erythropoietin / therapeutic use

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132904.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cytokines; 0 / Hemoglobin A, Glycosylated; 0 / Hemoglobins; 11096-26-7 / Erythropoietin
  •  go-up   go-down


26. Malcovati L, Della Porta MG, Pietra D, Boveri E, Pellagatti A, Gallì A, Travaglino E, Brisci A, Rumi E, Passamonti F, Invernizzi R, Cremonesi L, Boultwood J, Wainscoat JS, Hellström-Lindberg E, Cazzola M: Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood; 2009 Oct 22;114(17):3538-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
  • The combination of ringed sideroblasts 15% or greater and platelet count of 450 x 10(9)/L or greater was found in 19 subjects fulfilling the diagnostic criteria for refractory anemia with ringed sideroblasts (RARS) associated with marked thrombocytosis (RARS-T), and in 3 patients with primary myelofibrosis.
  • These observations suggest that RARS-T is indeed a myeloid neoplasm with both myelodysplastic and myeloproliferative features at the molecular and clinical levels and that it may develop from RARS through the acquisition of somatic mutations of JAK2, MPL, or other as-yet-unknown genes.
  • [MeSH-major] Anemia, Refractory, with Excess of Blasts / genetics. Anemia, Refractory, with Excess of Blasts / pathology. Thrombocytosis / genetics. Thrombocytosis / pathology

  • Genetic Alliance. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19692701.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Thrombopoietin; 143641-95-6 / MPL protein, human; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


27. Huls G, Mulder AB, Rosati S, van de Loosdrecht AA, Vellenga E, de Wolf JT: Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. Blood; 2010 Jul 15;116(2):180-2
Hazardous Substances Data Bank. PYRIDOXINE HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
  • Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the cytoreductive treatment might be beneficial for the thrombocytosis component but harmful for the RARS component.
  • As lenalidomide has shown to be efficacious in both myelodysplastic syndromes and myeloproliferative neoplasms, we have treated 2 RARS-T patients, who were transfusion dependent, with lenalidomide.
  • [MeSH-major] Anemia, Refractory / drug therapy. Anemia, Sideroblastic / drug therapy. Antineoplastic Agents / therapeutic use. Janus Kinase 2 / genetics. Thalidomide / analogs & derivatives. Thrombocytosis / drug therapy

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20194893.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anabolic Agents; 0 / Antineoplastic Agents; 11096-26-7 / Erythropoietin; 12001-76-2 / Vitamin B Complex; 4Z8R6ORS6L / Thalidomide; EC 2.7.10.2 / Janus Kinase 2; F0P408N6V4 / lenalidomide; KV2JZ1BI6Z / Pyridoxine
  •  go-up   go-down


28. Raya JM, Arenillas L, Domingo A, Bellosillo B, Gutiérrez G, Luño E, Piñán MA, Barbón M, Pérez-Sirvent ML, Muruzábal MJ, Yánez L, García L, Lemes A, Navarro JT, Elosegi A, Cortés MA, Villegas A, Durán MA, Ardanaz M, Florensa L, Grupo Español de Citología Hematológica, Working Group into the Asociación Española de Hematología y Hemoterapia: Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status. Int J Hematol; 2008 Nov;88(4):387-95
Genetic Alliance. consumer health - Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status.
  • The World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues (2001) defined a provisional entity named refractory anemia with ringed sideroblasts associated to marked thrombocytosis (RARS-MT).
  • Nevertheless, controversy exists regarding this platelet count "cut-off" value and, when RARS-MT was defined, the JAK2 mutation and its importance in the study of myeloproliferative disorders was unknown.
  • [MeSH-major] Anemia, Refractory / genetics. Anemia, Refractory / pathology. Janus Kinase 2 / genetics. Mutation, Missense. Thrombocytosis / genetics. Thrombocytosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18820995.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Investigator] Florensa L; Arenillas L; Bellosillo B; Woessner S; Domingo A; Alonso E; Rozman M; Gutiérrez G; Rozman M; Piñán MA; Letamendi G; Perez-Sirvent ML; Cervera J; Barbón M; García L; Lemes A; Molero T; Yáñez L; Olalla JI; Muruzabal MJ; Millá F; Navarro JT; Ardanaz M; Elosegui A; Hernandez-Santamaría T; Villegas A; Mateo M; Cortés MA; González-Ponte ML; Durán MA; Vallespí T; Raya JM; Martín T; Morabito L; Hernández-Nieto L
  •  go-up   go-down


29. Voigt W, Jordan K, Sippel C, Amoury M, Schmoll HJ, Wolf HH: Severe thrombocytosis and anemia associated with celiac disease in a young female patient: a case report. J Med Case Rep; 2008;2:96

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe thrombocytosis and anemia associated with celiac disease in a young female patient: a case report.
  • INTRODUCTION: Platelet counts exceeding 1.000 x 103/microl are usually considered secondary to another cause, particularly to chronic myeloproliferative disease (CMPD).
  • CASE PRESENTATION: Here we report the case of a young woman presenting with clinical signs of severe anemia.
  • Laboratory findings confirmed an iron-deficiency anemia associated with severe thrombocytosis of 1703 x 103/microl.
  • A potential mechanism for the association of iron-deficiency anemia and thrombocytosis is discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 1994 Mar;96(3):247-53 [8154513.001]
  • [Cites] Stem Cells. 1997;15(4):286-90 [9253112.001]
  • [Cites] Am J Gastroenterol. 1999 Mar;94(3):691-6 [10086653.001]
  • [Cites] Blood. 1999 May 15;93(10):3286-93 [10233880.001]
  • [Cites] Acta Haematol. 2000;103(3):152-6 [10940653.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Aug;14(8):897-900 [12172415.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1719-26 [7535585.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Aug;25(8):675-6 [12902931.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1211-9 [15028825.001]
  • [Cites] N Engl J Med. 2006 May 11;354(19):2034-45 [16687716.001]
  • [Cites] Arch Pathol Lab Med. 2006 Aug;130(8):1144-50 [16879015.001]
  • [Cites] Blood. 2007 Jan 15;109(2):412-21 [16973955.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2568-70 [12815143.001]
  • (PMID = 18380894.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2329657
  •  go-up   go-down


30. Shinnick KM, Eklund EA, McGarry TJ: Geminin deletion from hematopoietic cells causes anemia and thrombocytosis in mice. J Clin Invest; 2010 Dec;120(12):4303-15
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geminin deletion from hematopoietic cells causes anemia and thrombocytosis in mice.
  • Defects in the orderly pattern of hematopoietic cell division and differentiation can lead to leukemia, myeloproliferative disorders, or marrow failure; however, the factors that control this pattern are incompletely understood.
  • [MeSH-major] Anemia / genetics. Hematopoietic Stem Cells / metabolism. Nuclear Proteins / deficiency. Thrombocytosis / genetics


31. Steensma DP, Caudill JS, Pardanani A, McClure RF, Lasho TL, Tefferi A: MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count. Haematologica; 2006 Dec;91(12 Suppl):ECR57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.
  • Discovery of a constitutively activating point mutation of the Janus kinase 2 (JAK2) receptor-associated tyrosine kinase in patients with polycythemia vera (PV) and other BCR/ABL-negative myeloproliferative disorders prompted many groups around the world to examine diverse subsets of patients with myeloid diseases for the prevalence of the JAK2 V617F mutation and its clinical and pathological associations.
  • [MeSH-major] Anemia, Refractory / genetics. Anemia, Sideroblastic / genetics. Janus Kinase 2 / genetics. Mutation, Missense. Point Mutation. Receptors, Thrombopoietin / genetics

  • Genetic Alliance. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17194663.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K12 CA90628
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Receptors, Thrombopoietin; 143641-95-6 / MPL protein, human; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


32. Tokuhira M, Watanabe R, Iizuka A, Sekiguchi Y, Nemoto T, Hanzawa K, Takamatsu I, Maruyama T, Tamaru J, Itoyama S, Suzuki H, Takeuchi T, Mori S: De novo CD5+ diffuse large B cell lymphoma with basophilia in the peripheral blood: successful treatment with autologous peripheral blood stem cell transplantation. Am J Hematol; 2007 Feb;82(2):162-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Basophils play an important role in allergic inflammation and are pathologically related to hematological disturbances, such as iron deficiency anemia and myeloproliferative disorders; however, they are only rarely encountered in lymphoid malignancies.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17019691.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5
  •  go-up   go-down


33. Stella M, Serventi A, Friedman D: Right portal vein thrombosis after splenectomy for trauma. J Gastrointest Surg; 2005 May-Jun;9(5):646-7
MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Portal vein thrombosis may complicate splenectomy in patients with hemolytic anemia and myeloproliferative disease, whereas the frequency of portal vein thrombosis in case of trauma is not defined.

  • Genetic Alliance. consumer health - Portal thrombosis.
  • Genetic Alliance. consumer health - Portal vein thrombosis.
  • Genetic Alliance. consumer health - Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15862258.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants
  •  go-up   go-down


34. Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K: Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood; 2006 Sep 15;108(6):2041-4
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Somatic activation of a conditional targeted Kras(G12D) allele induces a fatal myeloproliferative disease in mice that closely models juvenile and chronic myelomonocytic leukemia.
  • These mice consistently develop severe and progressive anemia despite adequate numbers of clonogenic erythroid progenitors in the bone marrow and expanded splenic hematopoiesis.
  • These results demonstrate that endogenous levels of oncogenic Ras have cell lineage-specific effects and support efforts to modulate Ras signaling for therapy of anemia in patients with myelodysplastic syndromes and myeloproliferative disorders.


35. Kaferle J, Strzoda CE: Evaluation of macrocytosis. Am Fam Physician; 2009 Feb 1;79(3):203-8
MedlinePlus Health Information. consumer health - Blood Count Tests.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When the peripheral smear indicates megaloblastic anemia (demonstrated by macro-ovalocytes and hyper-segmented neutrophils), vitamin B12 or folate deficiency is the most likely cause.
  • Of other possible etiologies, hypothyroidism, liver disease, and primary bone marrow dysplasias (including myelodysplasia and myeloproliferative disorders) are some of the more common causes.
  • [MeSH-major] Anemia, Macrocytic / diagnosis. Anemia, Macrocytic / etiology. Blood Cell Count. Erythrocyte Indices
  • [MeSH-minor] Alcohol Drinking / adverse effects. Algorithms. Anemia, Megaloblastic / diagnosis. Anemia, Megaloblastic / etiology. Diagnosis, Differential. Drug-Related Side Effects and Adverse Reactions. Erythrocyte Count. FIGLU Test. Folic Acid Deficiency / complications. Humans. Hypothyroidism / complications. Liver Diseases / complications. Myeloproliferative Disorders / complications. Neural Tube Defects / complications. Predictive Value of Tests. Reticulocyte Count. Risk Factors. Sensitivity and Specificity. Vitamin B 12 Deficiency / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19202968.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


36. Yin CC, Medeiros LJ, Bueso-Ramos CE: Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification. Int J Lab Hematol; 2010 Oct;32(5):461-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Protein tyrosine kinase abnormalities, including translocations or mutations involving ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB, and FGFR1, have been used as the basis for classifying myeloproliferative neoplasms (MPN).
  • Two new entities - refractory cytopenia with unilineage dysplasia and refractory cytopenia of childhood have been added to the group of myelodysplastic syndromes (MDS), and 'refractory anemia with excess blasts-1' has been redefined to emphasize the prognostic significance of increased blasts in the peripheral blood.
  • [MeSH-major] Myelodysplastic Syndromes / classification. Myeloproliferative Disorders / classification
  • [MeSH-minor] Anemia, Refractory, with Excess of Blasts / classification. Humans. Leukemia, Myeloid, Acute / classification. Leukemia, Myeloid, Acute / diagnosis. Protein-Tyrosine Kinases / genetics

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20626469.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ NIHMS691453; NLM/ PMC4452117
  •  go-up   go-down


37. Bowen DT: Chronic myelomonocytic leukemia: lost in classification? Hematol Oncol; 2005 Mar;23(1):26-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic myelomonocytic leukemia (CMML) comprises a spectrum of disease variably considered as a myelodysplastic (MDS) and/or myeloproliferative (MPD) disorder.
  • The principal clinical difference between CMML and other MPD is the presence of ineffective hematopoiesis, manifesting as more frequent anemia and thrombocytopenia in CMML.
  • [MeSH-major] Leukemia, Myelomonocytic, Chronic / classification. Myelodysplastic Syndromes / classification. Myeloproliferative Disorders / classification


38. Kuriyama K: [Classification of myeloid leukemias]. Nihon Rinsho; 2009 Oct;67(10):1853-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The myeloid neoplasms are composed of six categories, which are 1) myeloproliferative neoplasms (MPN), a new category of 2) myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1, 3) myelodysplastic syndrome (MDS)/MPN, 4) MDS, 5) acute myeloid leukemia (AML) and related precursor neoplasms, and 6) acute leukemias of ambiguous lineage.
  • MDS has the new subtype of refractory cytopenia with unilineage dysplasia composed of refractory anemia, refractory neutropenia and refractory thrombocytopenia.
  • [MeSH-minor] Eosinophilia. Humans. Leukemia, Myeloid, Acute / genetics. Myelodysplastic Syndromes / genetics. Myeloproliferative Disorders / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics. Receptor, Platelet-Derived Growth Factor beta / genetics. World Health Organization

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860179.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  • [Number-of-references] 14
  •  go-up   go-down


39. Randi ML, Ruzzon E, Tezza F, Luzzatto G, Fabris F: Toxicity and side effects of hydroxyurea used for primary thrombocythemia. Platelets; 2005 May-Jun;16(3-4):181-4
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over the last 20 years a vast array of data has been accumulated on the efficacy of hydroxyurea (HU) in patients with Philadelphia-negative myeloproliferative disorders (MPD).
  • Unwanted side-effects (five symptomatic macrocytic anemia, two fever reactions, two allergic reactions, four cases each of leg painful ulcers, three acute leukemia or myelodysplasia) induced to withdraw therapy in 16 patients.
  • [MeSH-minor] Adult. Aged. Cause of Death. Cohort Studies. Dose-Response Relationship, Drug. Drug Evaluation. Female. Humans. Male. Middle Aged. Myeloproliferative Disorders / complications. Myeloproliferative Disorders / drug therapy. Retrospective Studies. Treatment Failure

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16011962.001).
  • [ISSN] 0953-7104
  • [Journal-full-title] Platelets
  • [ISO-abbreviation] Platelets
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


40. Singh DK, Mahajan D, Nigam S, Singh T: Osteomyelosclerosis with thalassemia trait: report of a rare association, study of platelet function tests and review of literature. Hematology; 2008 Apr;13(2):83-7
MedlinePlus Health Information. consumer health - Thalassemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Idiopathic myelofibrosis is a chronic myeloproliferative disorder characterized by excessive connective tissue deposition in the bone marrow.
  • It presents with leucoerythroblastic anemia and massive splenomegaly.
  • [MeSH-minor] Adult. Chronic Disease. Humans. India. Male. Myeloproliferative Disorders / diagnosis. Osteosclerosis / diagnosis. Platelet Function Tests

  • Genetic Alliance. consumer health - Thalassemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616873.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 25
  •  go-up   go-down


41. Schmitt-Graeff A, Hochhaus A: [Hematological side effects of tyrosine kinase inhibition using imatinib]. Pathologe; 2006 Feb;27(1):40-6
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imatinib (STI571, Gleevec/Glivec) and other small-molecule tyrosine kinase inhibitors are highly effective in the treatment of chronic myeloid leukemia (CML), gastrointestinal stromal tumors and, for example, eosinophilia-associated chronic myeloproliferative disorders.
  • Morphological features may be in keeping with either aplastic anemia or myelodysplasia developing in Philadelphia-negative hematopoiesis.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bone Marrow / pathology. Myeloproliferative Disorders / chemically induced. Piperazines / adverse effects. Protein Kinase Inhibitors / adverse effects. Pyrimidines / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16421705.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


42. Malcovati L, Cazzola M: Myelodysplastic/myeloproliferative disorders. Haematologica; 2008 Jan;93(1):4-6
MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelodysplastic/myeloproliferative disorders.
  • [MeSH-major] Medical Oncology / methods. Myelodysplastic Syndromes / diagnosis. Myeloproliferative Disorders / diagnosis
  • [MeSH-minor] Anemia / genetics. Gene Expression Regulation, Neoplastic. Humans. Janus Kinase 2 / genetics. Models, Biological. Mutation. Phenotype. Receptors, Thrombopoietin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Haematologica. 2008 Jan;93(1):34-40 [18166783.001]
  • (PMID = 18166777.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Receptors, Thrombopoietin; 143641-95-6 / MPL protein, human; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


43. Saraceno R, Teoli M, Chimenti S: Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject. Clin Ther; 2008 Jul;30(7):1324-9
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hydroxyurea is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with mucocutaneous adverse events and nail hyperpigmentation.
  • His current medication regimen was hydroxyurea (500 mg BID), iron (525 mg QD), and folic acid (15 mg QD) for the myeloproliferative disease and the associated anemia; spironolactone (25 mg BID) and furosemide (20 mg BID) for the complications of cirrhosis; allopurinol (100 mg QD) to treat gout; and theophylline (250 mg QD) for chronic bronchitis.
  • Based on the Naranjo algorithm, the adverse reaction observed was probably related to the hydroxyurea treatment (score = 6); however, the hydroxyurea chemotherapy could not be discontinued because of the myeloproliferative disorder.
  • The progressive appearance of squamous epitheliomas and other cutaneous adverse events, such as the ulcer, suggests that alternative chemotherapies should be considered for the treatment of myeloproliferative diseases.
  • [MeSH-minor] Aged, 80 and over. Aminoquinolines / therapeutic use. Humans. Male. Myeloproliferative Disorders / drug therapy

  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18691992.001).
  • [ISSN] 0149-2918
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


44. Wood L, Baker PM, Martindale A, Jacobs P: Splenectomy in haematology--a 5-year single centre experience. Hematology; 2005 Dec;10(6):505-9
MedlinePlus Health Information. consumer health - Blood Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Referrals were for immune thrombocytopaenia (41%), acquired haemolytic anaemia (10%), myeloproliferative syndrome (9%), acute or chronic leukaemia (19%), lymphoma (13%) and a miscellaneous group (8%), comprising cholelithiasis, aplasia or as a diagnostic procedure for otherwise unexplained splenomegaly.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anemia, Hemolytic / surgery. Child. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Lymphoma / surgery. Male. Middle Aged. Myeloproliferative Disorders / surgery. Retrospective Studies. Splenomegaly / etiology. Splenomegaly / surgery. Thrombocytopenia / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321816.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


45. Altintas A, Karahan Z, Pasa S, Cil T, Boyraz T, Iltumur K, Ayyildiz O: Pulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosis. Leuk Lymphoma; 2007 Oct;48(10):1981-7
MedlinePlus Health Information. consumer health - Pulmonary Hypertension.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased incidence of pulmonary hypertension (PH) has been reported in patients with chronic myeloproliferative disorders.
  • Previously or newly diagnosed 46 patients with ET, and 40 patients with reactive thrombocytosis secondary to iron deficiency anemia were found to be eligible for this study.
  • [MeSH-major] Hypertension, Pulmonary / complications. Myeloproliferative Disorders / complications. Pulmonary Artery / pathology


46. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL: JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood; 2006 Sep 1;108(5):1652-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A JAK2(V617F) mutation is frequently found in several BCR/ABL-negative myeloproliferative disorders.
  • To address the contribution of this mutant to the pathogenesis of these different myeloproliferative disorders, we used an adoptive transfer of marrow cells transduced with a retrovirus expressing JAK2(V617F) in recipient irradiated mice.
  • Development of fibrosis was associated with anemia, thrombocytopenia, high neutrophilia, and massive splenomegaly.
  • Questions remain regarding the exact contribution of JAK2(V617F) in other myeloproliferative disorders.
  • [MeSH-major] Hematopoietic Stem Cells / physiology. Myeloproliferative Disorders / physiopathology. Polycythemia Vera / physiopathology. Primary Myelofibrosis / physiopathology. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins / genetics

  • Genetic Alliance. consumer health - Myelofibrosis.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670266.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Jak2 protein, mouse; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


47. Schmitt-Graeff AH: [Chronic myeloid neoplasms. Diagnostic criteria and current therapeutic concepts]. Pathologe; 2010 Feb;31(1):29-41
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myeloproliferative neoplasms (MPNs) and related chronic disorders constitute a subgroup of myeloid malignancies which are defined according to clinical, morphological and molecular features by the actual World Health Organization classification of tumors of the haematopietic system.
  • Myelodysplastic/MPN overlap syndromes include rare entities such as refractory anemia with ringed sideroblasts characterized by a high proportion of JAK2V617F mutated cases.
  • [MeSH-minor] Alleles. Biomarkers, Tumor / genetics. Bone Marrow / pathology. DNA Mutational Analysis. Diagnosis, Differential. Humans. Leukemia, Myelomonocytic, Chronic / drug therapy. Leukemia, Myelomonocytic, Chronic / genetics. Leukemia, Myelomonocytic, Chronic / pathology. Molecular Diagnostic Techniques. Myeloproliferative Disorders / drug therapy. Myeloproliferative Disorders / genetics. Myeloproliferative Disorders / pathology. Polycythemia Vera / drug therapy. Polycythemia Vera / genetics. Polycythemia Vera / pathology. Primary Myelofibrosis / drug therapy. Primary Myelofibrosis / genetics. Primary Myelofibrosis / pathology. Prognosis. Protein-Tyrosine Kinases / antagonists & inhibitors. Signal Transduction / drug effects. Signal Transduction / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20076959.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 29
  •  go-up   go-down


48. Yang L, Wang L, Kalfa TA, Cancelas JA, Shang X, Pushkaran S, Mo J, Williams DA, Zheng Y: Cdc42 critically regulates the balance between myelopoiesis and erythropoiesis. Blood; 2007 Dec 1;110(12):3853-61
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cdc42-deficient mice developed a fatal myeloproliferative disorder manifested by significant leukocytosis with neutrophilia, myeloid hyperproliferation, and myeloid cell infiltration into distal organs.
  • Concurrently, Cdc42 deficiency caused anemia and splenomegaly accompanied with decreased bone marrow erythroid burst-forming units (BFU-Es) and colony-forming units-erythroid (CFU-Es) activities and reduced immature erythroid progenitors, suggesting that Cdc42 deficiency causes a block in the early stage of erythropoiesis.
  • [MeSH-minor] Anemia / enzymology. Anemia / genetics. Animals. CCAAT-Enhancer-Binding Proteins / biosynthesis. CCAAT-Enhancer-Binding Proteins / genetics. Cell Adhesion / genetics. Cell Movement / genetics. Cell Proliferation. Chemokine CXCL12 / pharmacology. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / genetics. Erythroid Precursor Cells / enzymology. Fibronectins / pharmacology. GATA2 Transcription Factor / biosynthesis. GATA2 Transcription Factor / genetics. Gene Deletion. Interleukin-3 / pharmacology. Mice. Mice, Knockout. Myeloid Progenitor Cells / enzymology. Myeloproliferative Disorders / enzymology. Myeloproliferative Disorders / genetics. Myeloproliferative Disorders / pathology. Proto-Oncogene Proteins / biosynthesis. Proto-Oncogene Proteins / genetics. Trans-Activators / biosynthesis. Trans-Activators / genetics. Transcription Factors / biosynthesis. Transcription Factors / genetics

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1998 Aug 3;17(15):4456-68 [9687512.001]
  • [Cites] J Cell Biol. 1998 Jun 1;141(5):1147-57 [9606207.001]
  • [Cites] Ann N Y Acad Sci. 1999 Apr 30;872:289-303; discussion 303-4 [10372131.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):547-52 [15607959.001]
  • [Cites] Exp Hematol. 2005 Feb;33(2):131-43 [15676205.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(15):6747-59 [16024808.001]
  • [Cites] Blood. 2006 Jan 1;107(1):98-105 [16174757.001]
  • [Cites] J Biol Chem. 2006 Apr 21;281(16):10745-51 [16500901.001]
  • [Cites] Int J Hematol. 2006 Jul;84(1):38-42 [16867900.001]
  • [Cites] Mol Biol Cell. 2006 Nov;17(11):4675-85 [16914516.001]
  • [Cites] Genes Dev. 2006 Nov 1;20(21):3010-21 [17079688.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4205-13 [16931627.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5091-6 [17360364.001]
  • [Cites] Eur J Immunol. 1999 Nov;29(11):3609-20 [10556816.001]
  • [Cites] Cell. 2000 Jan 7;100(1):143-55 [10647939.001]
  • [Cites] Nature. 2000 Mar 9;404(6774):193-7 [10724173.001]
  • [Cites] Blood. 2000 Aug 1;96(3):910-6 [10910904.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):57-64 [11262875.001]
  • [Cites] Int Rev Immunol. 2001 Feb;20(1):83-105 [11342299.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1086-94 [11493455.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3261-73 [11719363.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3368-76 [12032775.001]
  • [Cites] Blood. 2002 Jul 1;100(1):238-45 [12070033.001]
  • [Cites] Blood. 2002 Jul 15;100(2):483-90 [12091339.001]
  • [Cites] Immunity. 2002 Nov;17(5):665-76 [12433372.001]
  • [Cites] Nature. 2002 Dec 12;420(6916):629-35 [12478284.001]
  • [Cites] Exp Hematol. 2003 Jan;31(1):39-47 [12543105.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):836-41 [14574412.001]
  • [Cites] Blood. 2004 Jan 15;103(2):583-5 [14504093.001]
  • [Cites] Nature. 1994 Sep 15;371(6494):221-6 [8078582.001]
  • [Cites] Science. 1995 Sep 8;269(5229):1427-9 [7660125.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1383-93 [9028962.001]
  • [Cites] Cell. 1997 Feb 7;88(3):287-98 [9039255.001]
  • [Cites] Blood. 1997 Jul 15;90(2):489-519 [9226149.001]
  • [Cites] Genes Dev. 1997 Sep 15;11(18):2295-322 [9308960.001]
  • [Cites] Curr Opin Hematol. 1995 Jan;2(1):3-11 [9371966.001]
  • [Cites] Cell. 1997 Nov 28;91(5):661-72 [9393859.001]
  • [Cites] Stem Cells. 1998;16(1):25-37 [9474745.001]
  • [Cites] Eur J Immunol. 1998 Jul;28(7):2245-51 [9692894.001]
  • (PMID = 17702896.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA105117; United States / NHLBI NIH HHS / HL / R01 HL085362
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Proteins; 0 / Chemokine CXCL12; 0 / DNA-Binding Proteins; 0 / Fibronectins; 0 / GATA2 Transcription Factor; 0 / Gata2 protein, mouse; 0 / Gfi1 protein, mouse; 0 / Interleukin-3; 0 / Proto-Oncogene Proteins; 0 / Trans-Activators; 0 / Transcription Factors; 0 / proto-oncogene protein Spi-1; EC 3.6.5.2 / cdc42 GTP-Binding Protein
  • [Other-IDs] NLM/ PMC2190607
  •  go-up   go-down


49. Berentsen S, Ulvestad E, Langholm R, Beiske K, Hjorth-Hansen H, Ghanima W, Sørbø JH, Tjønnfjord GE: Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica; 2006 Apr;91(4):460-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autoimmune diseases other than CAD were reported in 8% of patients, cold-induced circulatory symptoms in 91%, and exacerbation of hemolytic anemia during febrile illness in 74%.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chronic Disease. Female. Follow-Up Studies. Humans. Male. Middle Aged. Myeloproliferative Disorders. Norway / epidemiology. Retrospective Studies


50. Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, Boggi S, Astori C, Bernasconi P, Varettoni M, Brusamolino E, Pascutto C, Lazzarino M: Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica; 2008 Nov;93(11):1645-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Essential thrombocythemia is a chronic myeloproliferative disorder; patients with this disorder have a propensity to develop thrombosis, myelofibrosis, and leukemia.
  • Anemia at diagnosis of essential thrombocythemia was significantly correlated (p<0.001) with progression to myelofibrosis.
  • [MeSH-major] Leukemia / physiopathology. Myeloproliferative Disorders / genetics. Primary Myelofibrosis / physiopathology. Thrombocythemia, Essential / complications. Thrombosis / physiopathology


51. Hellström-Lindberg E, Cazzola M: The role of JAK2 mutations in RARS and other MDS. Hematology Am Soc Hematol Educ Program; 2008;:52-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acquired sideroblastic anemia with unilineage dysplasia (WHO RARS) is a clonal stem cell disorder characterized by erythroid dysplasia, mitochondrial accumulation of mitochondrial ferritin, defective erythroid maturation and anemia.
  • It has recently been described that around half of RARS-T patients, along with a small subset of other MDS and mixed myelodysplastic/ myeloproliferative disorders, carry the JAK2 mutation, and that MPL mutations are found in single patients.
  • However, the degree of anemia and overall survival is more similar to RARS than myeloproliferative disorders.

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074058.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 43
  •  go-up   go-down


52. Oliva EN, Ronco F, Marino A, Alati C, Praticò G, Nobile F: Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion; 2010 Jul;50(7):1568-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN AND METHODS: Among chronically transfused adults affected by myeloproliferative neoplasms and treated with iron chelators, two case reports are described.
  • CASE REPORT: A male adult patient with myelodysplastic syndrome (MDS) and a female adult with aplastic anemia (AA), both transfusion-dependent, were treated with deferasirox, an oral iron chelator.
  • CONCLUSION: Although there are few reports on erythroid responses in patients undergoing iron chelation therapy, they may give new insights in the pathogenesis of MDS and other myeloproliferative neoplasms.
  • A survival benefit of chelation in patients with myeloproliferative neoplasms is still to be confirmed.
  • [MeSH-minor] Anemia, Aplastic / blood. Anemia, Aplastic / therapy. Female. Humans. Male. Middle Aged. Myelodysplastic Syndromes / blood. Myelodysplastic Syndromes / therapy

  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20230535.001).
  • [ISSN] 1537-2995
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzoates; 0 / Iron Chelating Agents; 0 / Triazoles; V8G4MOF2V9 / deferasirox
  •  go-up   go-down


53. Porse BT, Bryder D, Theilgaard-Mönch K, Hasemann MS, Anderson K, Damgaard I, Jacobsen SE, Nerlov C: Loss of C/EBP alpha cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocyte lineage. J Exp Med; 2005 Jul 4;202(1):85-96
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We now show that such mutations increase the capacity of bone marrow (BM) myeloid progenitors to proliferate, and predispose mice to a granulocytic myeloproliferative disorder and transformation of the myeloid compartment of the BM.
  • Circulating myeloblasts and hepatic leukocyte infiltration were observed, but thrombocytopenia, anemia, and elevated leukocyte count--normally associated with AML-were absent.
  • [MeSH-minor] Animals. Bone Marrow Transplantation. Cell Differentiation. Cell Proliferation. Cell Transformation, Neoplastic / genetics. Humans. Leukemia, Myeloid, Acute / genetics. Mice. Mice, Inbred C57BL. Mice, Mutant Strains. Mutation. Myeloproliferative Disorders / etiology. Myeloproliferative Disorders / genetics. Myeloproliferative Disorders / pathology. Phenotype

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell. 2001 Oct;8(4):817-28 [11684017.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):569-74 [9012825.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1332-40 [11830484.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):63-74 [12086889.001]
  • [Cites] Blood. 2002 Jul 15;100(2):483-90 [12091339.001]
  • [Cites] Mol Cell Biol. 2002 Aug;22(15):5506-17 [12101243.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):31-7 [12109853.001]
  • [Cites] Blood. 2002 Aug 1;100(3):998-1007 [12130514.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):148-52 [12172547.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2717-23 [12351377.001]
  • [Cites] Blood. 2003 Jan 1;101(1):270-7 [12393465.001]
  • [Cites] Leukemia. 2003 Feb;17(2):343-9 [12592334.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):5302-7 [9144232.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1997 Jul 15;90(2):489-519 [9226149.001]
  • [Cites] Cell. 1997 Nov 28;91(5):661-72 [9393859.001]
  • [Cites] Mol Cell Biol. 1998 Jan;18(1):322-33 [9418879.001]
  • [Cites] Cell Growth Differ. 1998 Jan;9(1):59-69 [9438389.001]
  • [Cites] Mol Cell Biol. 1998 Jul;18(7):4301-14 [9632814.001]
  • [Cites] Immunity. 1998 Jul;9(1):47-57 [9697835.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2403-12 [9694804.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2413-23 [9694805.001]
  • [Cites] Immunity. 2004 Dec;21(6):853-63 [15589173.001]
  • [Cites] Blood. 2000 Jan 15;95(2):726-7 [10660321.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):193-207 [10697278.001]
  • [Cites] Nature. 2000 Mar 9;404(6774):193-7 [10724173.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):5986-97 [10913181.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):263-70 [11242107.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):57-64 [11262875.001]
  • [Cites] Nat Med. 2001 Apr;7(4):444-51 [11283671.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(11):3789-806 [11340171.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1166-73 [11493466.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10398-403 [11526243.001]
  • [Cites] J Exp Med. 2001 Oct 1;194(7):941-52 [11581316.001]
  • [Cites] Cell. 2001 Oct 19;107(2):247-58 [11672531.001]
  • [Cites] Immunity. 2001 Oct;15(4):659-69 [11672547.001]
  • [Cites] Genes Chromosomes Cancer. 2003 May;37(1):72-8 [12661007.001]
  • [Cites] Oncogene. 2003 May 1;22(17):2548-57 [12730669.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4760-4 [12879022.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1267-75 [12702500.001]
  • [Cites] Nat Immunol. 2003 Oct;4(10):1029-36 [12958595.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3163-71 [12869508.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):394-400 [15122210.001]
  • [Cites] Nat Genet. 2004 Jun;36(6):624-30 [15146183.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1639-47 [15073037.001]
  • [Cites] Nature. 2004 Oct 21;431(7011):1002-7 [15457180.001]
  • [Cites] Nature. 1990 Mar 15;344(6263):251-3 [2179728.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8219-23 [8367486.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1573-7 [8079170.001]
  • [Cites] Science. 1995 Aug 25;269(5227):1108-12 [7652557.001]
  • [Cites] Genes Dev. 1996 Apr 1;10(7):804-15 [8846917.001]
  • [Cites] EMBO J. 1996 Oct 15;15(20):5647-58 [8896458.001]
  • [Cites] Blood. 1997 Jan 15;89(2):376-87 [9002938.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):48-58 [11753385.001]
  • (PMID = 15983063.001).
  • [ISSN] 0022-1007
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Protein-alpha
  • [Other-IDs] NLM/ PMC2212897
  •  go-up   go-down


54. Ciovacco WA, Raskind WH, Kacena MA: Human phenotypes associated with GATA-1 mutations. Gene; 2008 Dec 31;427(1-2):1-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These five human diseases are: X-linked thrombocytopenia (XLT), X-linked thrombocytopenia with thalassemia (XLTT), congenital erythropoietic porphyria (CEP), transient myeloproliferative disorder (TMD) and acute megarakaryoblastic leukemia (AMKL) associated with Trisomy 21, and, lastly, a particular subtype of anemia associated with the production of GATA-1s, a shortened, mutant isoform of the wild-type GATA-1.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):502-13 [12094236.001]
  • [Cites] J Exp Med. 2002 Jun 3;195(11):1379-86 [12045236.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2040-5 [12200364.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):148-52 [12172547.001]
  • [Cites] Acta Haematol. 2002;108(4):237-45 [12432220.001]
  • [Cites] J Exp Med. 2003 Feb 3;197(3):281-96 [12566412.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4333-41 [12576332.001]
  • [Cites] EMBO J. 2003 Dec 15;22(24):6516-25 [14657024.001]
  • [Cites] Thromb Haemost. 2004 Jan;91(1):129-40 [14691578.001]
  • [Cites] Nat Med. 2004 Mar;10(3):299-304 [14966519.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2480-9 [14656875.001]
  • [Cites] Tohoku J Exp Med. 1984 Jul;143(3):261-87 [6484975.001]
  • [Cites] Clin Chem. 1986 Jul;32(7):1255-63 [3521939.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Aug;85(16):5976-80 [3413070.001]
  • [Cites] Nature. 1989 Jun 8;339(6224):446-51 [2725678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(2):668-72 [2300555.001]
  • [Cites] Nature. 1991 Jan 17;349(6306):257-60 [1987478.001]
  • [Cites] Genes Dev. 1994 May 15;8(10):1184-97 [7926723.001]
  • [Cites] Development. 1995 Jan;121(1):163-72 [7867497.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12355-8 [8901585.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1642-51 [9032291.001]
  • [Cites] Cell. 1997 Jul 11;90(1):109-19 [9230307.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3965-73 [9233806.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2680-9 [9326235.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):166-75 [10508512.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):11-20 [15630411.001]
  • [Cites] Semin Cell Dev Biol. 2005 Feb;16(1):137-47 [15659348.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4369-76 [15701726.001]
  • [Cites] EMBO J. 2005 Jul 6;24(13):2367-78 [15920470.001]
  • [Cites] Acta Haematol. 2005;114(2):113-6 [16103636.001]
  • [Cites] Int J Hematol. 2005 Jun;81(5):378-84 [16158817.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):807-12 [16783379.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):741-2 [16804537.001]
  • [Cites] Mol Cell Biol. 2006 Oct;26(19):7056-67 [16980610.001]
  • [Cites] Curr Opin Pediatr. 2007 Feb;19(1):9-14 [17224656.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2618-21 [17148589.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3297-9 [17209061.001]
  • [Cites] Platelets. 2007 Sep;18(6):436-50 [17763153.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2770-1; author reply 2771 [17881640.001]
  • [Cites] Platelets. 2007 Dec;18(8):620-7 [18041654.001]
  • [Cites] Nature. 1990 Mar 29;344(6265):444-7 [2320112.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):266-70 [10700180.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2262-8 [10733494.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3727-32 [11389009.001]
  • [Cites] Blood. 2001 Jul 1;98(1):85-92 [11418466.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2681-8 [11675338.001]
  • [Cites] Hum Mol Genet. 2002 Jan 15;11(2):147-52 [11809723.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9237-42 [12077323.001]
  • (PMID = 18930124.001).
  • [ISSN] 0378-1119
  • [Journal-full-title] Gene
  • [ISO-abbreviation] Gene
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK072442; United States / NIAMS NIH HHS / AR / AR055269-02; United States / NIAMS NIH HHS / AR / R03 AR055269-02; United States / NIAMS NIH HHS / AR / R03 AR055269; United States / NIDDK NIH HHS / DK / DK0724429; United States / NIAMS NIH HHS / AR / AR055269; United States / NIDDK NIH HHS / DK / DK072442-02; United States / NIDDK NIH HHS / DK / P30 DK072442-02; United States / NIAMS NIH HHS / AR / R03 AR055269-01; United States / NIAMS NIH HHS / AR / AR055269-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human
  • [Other-IDs] NLM/ NIHMS80104; NLM/ PMC2601579
  •  go-up   go-down


55. Wong KF, Wong WS, Siu LL, Lau TC, Chan NP: JAK2 V617F mutation is associated with 5q- syndrome in Chinese. Leuk Lymphoma; 2009 Aug;50(8):1333-5
MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • JAK2 V617F mutation is mostly seen in BCR-ABLI negative myeloproliferative neoplasms.
  • Among other myeloid neoplasms, it occurs with remarkably high frequency in refractory anemia with ring sideroblasts associated with marked thrombocytosis, a group of myeloid neoplasms with both dysplastic and proliferative features.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia, Refractory, with Excess of Blasts / enzymology. Anemia, Refractory, with Excess of Blasts / genetics. Codon / genetics. Disease Progression. Female. Hong Kong / epidemiology. Humans. Karyotyping. Leukemia, Myeloid, Acute / enzymology. Leukemia, Myeloid, Acute / genetics. Middle Aged. Retrospective Studies. Syndrome

  • Genetic Alliance. consumer health - 5q- Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562618.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


56. Gru AA, Hassan A, Pfeifer JD, Huettner PC: Uterine extramedullary hematopoiesis: what is the clinical significance? Int J Gynecol Pathol; 2010 Jul;29(4):366-73
MedlinePlus Health Information. consumer health - Uterine Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have shown its association with myelofibrosis and myeloid metaplasia, chronic myeloproliferative disorders, and other hematologic malignancies in up to two-thirds of the cases.
  • Twelve of 20 patients had underlying anemia (mean Hgb of 11 mg/dL, range: 5.5 to 15.7 mg/dL).
  • None of the patients developed a significant hematologic disorder other than anemia during follow-up.
  • On the basis of our study, UEMH is frequently associated with chronic anemia.
  • [MeSH-major] Anemia / complications. Hematopoiesis, Extramedullary / physiology. Uterine Diseases / complications

  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20567151.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins
  •  go-up   go-down


57. Kotru M, Batra M, Gomber S, Rusia U: Transient thrombocytosis with megathrombocytes in a case of acute myeloblastic leukemia. Indian J Pathol Microbiol; 2009 Jan-Mar;52(1):113-4
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thrombocytosis is commonly seen in reactive conditions and certain neoplastic states, such as chronic myeloproliferative disorders.
  • Her hemogram revealed anemia (Hb-6.4g/dl), leucopenia (TLC - 1.2 x 109/L) and thrombocytosis (platelet count- 580 x 109/L).
  • [MeSH-minor] Anemia / etiology. Child. Female. Humans. Pyoderma / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136802.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


58. Tefferi A: New insights into the pathogenesis and drug treatment of myelofibrosis. Curr Opin Hematol; 2006 Mar;13(2):87-92
Genetic Alliance. consumer health - Myelofibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Myelofibrosis with myeloid metaplasia was first described in 1879, classified as a myeloproliferative disorder in 1951, and characterized as a clonal stem cell disorder in 1978.
  • Advances have also been meager in terms of treatment for disease complications, including anemia, splenomegaly, and leukemic transformation.
  • RECENT FINDINGS: At the molecular level, a JAK2 tyrosine kinase mutation (JAK2) has recently been described in a spectrum of myeloproliferative disorders including myelofibrosis with myeloid metaplasia with the reported mutational frequency ranging from 35% to 57% with 9-29% homozygosity.
  • [MeSH-minor] Anemia / drug therapy. Animals. Humans. Mice. Splenomegaly / drug therapy. Translocation, Genetic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456374.001).
  • [ISSN] 1065-6251
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 51
  •  go-up   go-down


59. Jelić-Puskarić B, Ostojić-Kolonić S, Planinc-Peraica A, Obad-Kovacević D, Kardum-Skelin I, Jaksić B: Myeloid sarcoma involving the breast. Coll Antropol; 2010 Jun;34(2):641-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of myeloid sarcoma may precede or concur with acute or chronic myeloid leukemia (AML or CML) or other myeloproliferative diseases or myelodysplastic syndromes (MDS).
  • Additional work-up revealed anemia, thrombocytopenia and leukocytosis, along with atypical blasts detected in peripheral blood and bone marrow smear.
  • [MeSH-minor] Adult. Anemia / etiology. Anemia / pathology. Biopsy, Fine-Needle. Bone Marrow / pathology. Fatal Outcome. Female. Humans. Leukemia, Myeloid, Acute / pathology. Leukocytosis / etiology. Leukocytosis / pathology. Recurrence. Thrombocytopenia / etiology. Thrombocytopenia / pathology

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698144.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


60. Colin Y, Rahuel C, Wautier MP, El Nemer W, Filipe A, Cartron JP, Le Van Kim C, Wautier JL: Red cell and endothelial Lu/BCAM beyond sickle cell disease. Transfus Clin Biol; 2008 Dec;15(6):402-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Lu/BCAM adhesion glycoproteins were first identified as laminin-10/11 erythroid receptors involved in RBC adhesion to endothelium in sickle cell anemia.
  • More recently, we demonstrated that constitutive phosphorylation of Lu/BCAM is also involved in abnormal RBC adhesion to endothelium in patients with polycythemia vera (PV), a frequent myeloproliferative disorders associated with the V617F mutation of the tyrosine kinase JAK2 leading to continuous stimulation of erythropoiesis.
  • [MeSH-major] Anemia, Sickle Cell / blood. Erythrocytes / pathology. Lutheran Blood-Group System / genetics

  • Genetic Alliance. consumer health - Sickle Cell Disease.
  • MedlinePlus Health Information. consumer health - Sickle Cell Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948049.001).
  • [ISSN] 1246-7820
  • [Journal-full-title] Transfusion clinique et biologique : journal de la Société française de transfusion sanguine
  • [ISO-abbreviation] Transfus Clin Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Lutheran Blood-Group System; 1F7A44V6OU / Colforsin
  •  go-up   go-down


61. McGrattan P, Logan A, Humphreys M, Bowers M: Jumping translocation in acute monocytic leukemia (M5b) with alternative breakpoint sites in the long arm of donor chromosome 3. Med Oncol; 2010 Sep;27(3):667-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An 86-year-old man presented with acute hepatic failure, worsening thrombocytopenia, and anemia having been diagnosed and managed expectantly with cytogenetically normal RAEB-1.
  • There have been fewer than 70 cases of acquired JTs reported in the literature, including one myeloproliferative neoplasm and five acute myeloid leukemias involving a single breakpoint site on donor chromosome 3.
  • [MeSH-minor] Aged, 80 and over. Anemia, Refractory, with Excess of Blasts / genetics. Disease Progression. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19629764.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Schalk E, Heim MU, Koenigsmann M, Jentsch-Ullrich K: Use of capillary blood count parameters in adults. Vox Sang; 2007 Nov;93(4):348-53
Biospecimen Research Database. Biospecimen Research Database .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Anemia / diagnosis. Blood Cell Count / methods. Blood Specimen Collection / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Leukemia / blood. Lymphoma / blood. Male. Middle Aged. Myelodysplastic-Myeloproliferative Diseases / blood

  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Blood Count Tests.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070280.001).
  • [ISSN] 0042-9007
  • [Journal-full-title] Vox sanguinis
  • [ISO-abbreviation] Vox Sang.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


63. Mesa RA, Quintás-Cardama A, Verstovsek S: Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia. Curr Hematol Malig Rep; 2007 Feb;2(1):25-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myelofibrosis with myeloid metaplasia (MMM) is currently classified as a classic (ie, BCR-ABL-negative) myeloproliferative disorder characterized by anemia, multiorgan extramedullary hematopoiesis, constitutional symptoms, and premature death from either leukemic transformation or other disease complications.
  • [MeSH-minor] Aged. Alkylating Agents / therapeutic use. Anemia / drug therapy. Anemia / etiology. Antimetabolites, Antineoplastic / therapeutic use. Blood Coagulation Disorders / drug therapy. Blood Coagulation Disorders / etiology. Disease Progression. Drug Delivery Systems. Drugs, Investigational / therapeutic use. Erythropoietin / therapeutic use. Hematopoiesis, Extramedullary / drug effects. Humans. Immunologic Factors / therapeutic use. Janus Kinase 2 / antagonists & inhibitors. Janus Kinase 2 / genetics. Leukemia, Myeloid, Acute / drug therapy. Middle Aged. Mutation, Missense. Palliative Care. Point Mutation. Protein Kinase Inhibitors / pharmacology. Protein Kinase Inhibitors / therapeutic use. Signal Transduction / drug effects. Thrombocytopenia / drug therapy. Thrombocytopenia / etiology

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425385.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Antimetabolites, Antineoplastic; 0 / Drugs, Investigational; 0 / Immunologic Factors; 0 / Protein Kinase Inhibitors; 11096-26-7 / Erythropoietin; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 76
  •  go-up   go-down


64. Hollanda LM, Lima CS, Cunha AF, Albuquerque DM, Vassallo J, Ozelo MC, Joazeiro PP, Saad ST, Costa FF: An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet; 2006 Jul;38(7):807-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acquired somatic mutations in exon 2 of the hematopoietic transcription factor GATA-1 have been found in individuals with Down syndrome with both transient myeloproliferative disorder and acute megakaryoblastic leukemia.
  • Hematological profiles of affected males demonstrate macrocytic anemia, normal platelet counts and neutropenia in most cases.
  • [MeSH-minor] Adolescent. Adult. Anemia, Macrocytic / blood. Anemia, Macrocytic / genetics. Anemia, Macrocytic / pathology. Animals. Blood Platelets / metabolism. Blood Platelets / ultrastructure. Bone Marrow / pathology. Child. Child, Preschool. Female. Humans. Infant. Male. Mice. Microscopy, Electron. Pedigree. Protein Isoforms / chemistry. Protein Isoforms / genetics. Protein Isoforms / metabolism

  • COS Scholar Universe. author profiles.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Genet. 2006 Jul;38(7):741-2 [16804537.001]
  • (PMID = 16783379.001).
  • [ISSN] 1061-4036
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human; 0 / Protein Isoforms
  •  go-up   go-down


65. Kelley TW, Parker CJ: CD4 (+)CD25 (+)Foxp3 (+) regulatory T cells and hematologic malignancies. Front Biosci (Schol Ed); 2010;2:980-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Acute Disease. Anemia, Aplastic / immunology. Animals. Female. Forkhead Transcription Factors / metabolism. Hodgkin Disease / immunology. Humans. Leukemia / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Lymphoma, Follicular / immunology. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, T-Cell, Cutaneous / immunology. Male. Multiple Myeloma / immunology. Myelodysplastic Syndromes / immunology. Myeloproliferative Disorders / immunology. Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20515837.001).
  • [ISSN] 1945-0524
  • [Journal-full-title] Frontiers in bioscience (Scholar edition)
  • [ISO-abbreviation] Front Biosci (Schol Ed)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  • [Number-of-references] 100
  •  go-up   go-down


66. Alford KA, Slender A, Vanes L, Li Z, Fisher EM, Nizetic D, Orkin SH, Roberts I, Tybulewicz VL: Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome. Blood; 2010 Apr 8;115(14):2928-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DS children have greatly increased rates of acute lymphoblastic leukemia and acute megakaryoblastic leukemia (AMKL); DS newborns present with transient myeloproliferative disorder (TMD), a preleukemic form of AMKL.
  • We show that although Tc1 mice do not develop leukemia, they have macrocytic anemia and increased extramedullary hematopoiesis.

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene. 2003 Oct 30;318:137-47 [14585506.001]
  • [Cites] Blood. 2003 Aug 1;102(3):981-6 [12649131.001]
  • [Cites] Nat Rev Genet. 2004 Oct;5(10):725-38 [15510164.001]
  • [Cites] Am J Med Genet. 1983 Oct;16(2):173-7 [6228141.001]
  • [Cites] Prog Clin Biol Res. 1990;360:263-80 [2147289.001]
  • [Cites] Am J Med Genet. 1993 Jun 15;46(5):510-2 [8322810.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1993 Nov;15(4):392-9 [8214361.001]
  • [Cites] Arch Pediatr Adolesc Med. 1995 Jul;149(7):824-5 [7795778.001]
  • [Cites] Arch Biochem Biophys. 1997 Aug 15;344(2):424-32 [9264557.001]
  • [Cites] Nat Genet. 2005 Jun;37(6):613-9 [15895080.001]
  • [Cites] Ann N Y Acad Sci. 2005 Jun;1044:142-58 [15958708.001]
  • [Cites] Br J Haematol. 2000 Sep;110(3):512-24 [10997960.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):148-52 [12172547.001]
  • [Cites] Lancet. 2003 May 10;361(9369):1617-20 [12747884.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4298-300 [12560215.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4333-41 [12576332.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4301-4 [12586620.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2960-8 [12816863.001]
  • [Cites] Science. 2005 Sep 23;309(5743):2033-7 [16179473.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3339-44 [16492768.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):807-12 [16783379.001]
  • [Cites] Am J Med Genet A. 2007 Jan 1;143A(1):42-50 [17163522.001]
  • [Cites] Blood Cells Mol Dis. 2007 Sep-Oct;39(2):156-9 [17532652.001]
  • [Cites] Blood. 2008 Jan 15;111(2):767-75 [17901249.001]
  • [Cites] J Exp Med. 2008 Mar 17;205(3):585-94 [18299402.001]
  • [Cites] Learn Mem. 2008 Jul;15(7):492-500 [18626093.001]
  • [Cites] Br J Haematol. 2008 Oct;143(2):300-3 [18699852.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4507-11 [18689547.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4503-6 [18812473.001]
  • [Cites] Blood. 2009 Feb 26;113(9):1929-37 [19109561.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2619-28 [19139078.001]
  • [Cites] Hum Mol Genet. 2009 Apr 15;18(8):1449-63 [19181682.001]
  • [Cites] Blood. 2009 Apr 2;113(14):3337-47 [19168790.001]
  • [Cites] Cancer Res. 2009 Jun 1;69(11):4665-73 [19487285.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2480-9 [14656875.001]
  • (PMID = 20154221.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United Kingdom / Medical Research Council / / G0601056; United Kingdom / Medical Research Council / / MC/ U117527252; United States / NHLBI NIH HHS / HL / R01 HL032259; United Kingdom / Medical Research Council / / U117527252
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human; 0 / Gata1 protein, mouse
  • [Other-IDs] NLM/ PMC2854435
  •  go-up   go-down


67. Gérard J, Dubois-Galopin F, Gardembas-Pain M, Defaux JB, Schmidt-Tanguy A, Godon A, Geneviève F, Blanchet O, Ifrah N, Zandecki M: [Refractory anaemia with ringed sideroblasts (RARS) associated with marked thrombocytosis: a provisional entity in the WHO classification of haematological malignancies]. Ann Biol Clin (Paris); 2005 Nov-Dec;63(6):653-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The WHO classification describes a group of myelodysplastic/myeloproliferative diseases, including a provisional entity, refractory anaemia with ringed sideroblasts (RARS) associated with marked thrombocytosis, underlining that is a provisional entity without consensus of belonging to myelodysplastic rather than to myeloproliferative syndromes.
  • The second case is a typical RARS, who developed a thrombocytosis after several years and emphasizes that a link, at least progressive, exists between RARS and myeloproliferative disorders.
  • The cases of RARS + marked thrombocytosis reported in the literature are few in number and do not allow to settle between a particular form of myelodysplastic syndrome and a myeloproliferative disorder, a fully justified reason to classify these patients in a temporary group.
  • [MeSH-major] Anemia, Sideroblastic / classification. Anemia, Sideroblastic / complications. Thrombocytosis / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330386.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 11
  •  go-up   go-down


68. Silver RT: Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate. Curr Hematol Rep; 2005 May;4(3):235-7
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Polycythemia vera (PV) is a myeloproliferative disease which if untreated leads to thrombohemorrhagic complications and eventually to progressive myelofibrosis of the marrow, anemia, and splenomegaly.

  • Genetic Alliance. consumer health - Polycythemia vera.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15865878.001).
  • [ISSN] 1541-0714
  • [Journal-full-title] Current hematology reports
  • [ISO-abbreviation] Curr. Hematol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Immunologic Factors; 0 / Interferon Type I; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Recombinant Proteins; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 19
  •  go-up   go-down


69. Silver RT: Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate. Curr Hematol Malig Rep; 2007 Feb;2(1):43-6
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Polycythemia vera is a myeloproliferative disease, which, if untreated, leads to thrombohemorrhagic complications and eventually to progressive myelofibrosis, anemia, and splenomegaly.

  • Genetic Alliance. consumer health - Polycythemia vera.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425387.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Interferon Type I; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Recombinant Proteins; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 26
  •  go-up   go-down


70. Reilly JT: Idiopathic myelofibrosis: pathogenesis to treatment. Hematol Oncol; 2006 Jun;24(2):56-63
Genetic Alliance. consumer health - Myelofibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Idiopathic myelofibrosis (IMF) is the least common of the chronic myeloproliferative disorders and carries the worst prognosis with a median survival of 4 years.
  • [MeSH-minor] Anemia / etiology. Anemia / therapy. Cytokines / physiology. Growth Hormone / physiology. Humans. Prognosis. Splenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16477581.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 9002-72-6 / Growth Hormone
  • [Number-of-references] 115
  •  go-up   go-down


71. Rosti V, Massa M, Vannucchi AM, Bergamaschi G, Campanelli R, Pecci A, Viarengo G, Meli V, Marchetti M, Guglielmelli P, Bruno E, Xu M, Hoffman R, Barosi G, Italian Registry of Myelofibrosis with Myeloid Metaplasia, Myeloproliferative Disorders Research Consortium: The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis; 2007 May-Jun;38(3):280-6
Genetic Alliance. consumer health - Myelofibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CXCR4 down-regulation was associated with advanced patient age, the presence of severe anemia, thrombocytopenia, and degree of bone marrow fibrosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17350297.001).
  • [ISSN] 1079-9796
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 108671-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers; 0 / RNA, Messenger; 0 / Receptors, CXCR4
  •  go-up   go-down


72. Dupriez B, Demory JL: [Myelofibrosis with myeloid metaplasia: diagnosis and treatment]. Rev Prat; 2005 Oct 15;55(15):1680-5
Genetic Alliance. consumer health - Myelofibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myelofibrosis with myeloid metaplasia is the rarest myeloproliferative syndrom.
  • Evolution is highly variable with a median overal survival of 40 to 60 months and numerous prognostic factors especially anemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334205.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 13
  •  go-up   go-down


73. Bowling MR, Cauthen CG, Perry CD, Patel NP, Bergman S, Link KM, Sane AC, Conforti JF: Pulmonary extramedullary hematopoiesis. J Thorac Imaging; 2008 May;23(2):138-41
Hazardous Substances Data Bank. AZATHIOPRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There have been several reports of patients presenting with pulmonary EMH published in the literature and the majority are due to a secondary process, such as myeloproliferative disorders, hemolytic anemias, hereditary spherocytosis, and Gaucher disease.
  • [MeSH-minor] Anemia, Hemolytic / etiology. Antirheumatic Agents / therapeutic use. Arthritis / complications. Azathioprine / therapeutic use. Biopsy, Fine-Needle. Diagnosis, Differential. Dry Eye Syndromes / etiology. Dyspnea / etiology. Female. Humans. Middle Aged. Pleural Effusion / etiology. Pulmonary Fibrosis / complications. Raynaud Disease / etiology. Sjogren's Syndrome / complications. Sjogren's Syndrome / drug therapy. Sleep Apnea, Obstructive / complications. Tomography, X-Ray Computed. Vasculitis / complications

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520574.001).
  • [ISSN] 0883-5993
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antirheumatic Agents; MRK240IY2L / Azathioprine
  •  go-up   go-down


74. Naithani R, Tyagi S, Choudhry VP: Secondary myelofibrosis in children. J Pediatr Hematol Oncol; 2008 Mar;30(3):196-8
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myelofibrosis is a rare childhood myeloproliferative disorder.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Examination. Child. Child, Preschool. Fanconi Anemia / complications. Female. Follow-Up Studies. Humans. Male. Methylprednisolone / therapeutic use. Predictive Value of Tests. Prognosis. Rare Diseases. Remission Induction. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376280.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


75. Ziarkiewicz M, Dwilewicz-Trojaczek J, Pastwińska A, Chmarzyńska E, Paszkowska-Kowalewska M, Koperski Ł, Jędrzejczak WW, Ziarkiewicz-Wróblewska B: Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome. Pol J Pathol; 2010;61(2):105-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) is a rare entity belonging to myeloproliferative/myelodysplastic syndromes.
  • [MeSH-major] Anemia, Refractory / pathology. Anemia, Sideroblastic / pathology. Thrombocytosis / pathology
  • [MeSH-minor] Aged. Anemia, Macrocytic / drug therapy. Anemia, Macrocytic / genetics. Anemia, Macrocytic / pathology. Antineoplastic Agents / therapeutic use. Bone Marrow Cells / pathology. Chromosome Deletion. Chromosomes, Human, Pair 5 / genetics. Drug Therapy, Combination. Humans. Hydroxyurea / therapeutic use. In Situ Hybridization, Fluorescence. Male. Thalidomide / analogs & derivatives. Thalidomide / therapeutic use

  • Genetic Alliance. consumer health - 5q- Syndrome.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20924996.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide; X6Q56QN5QC / Hydroxyurea; Chromosome 5q Deletion Syndrome
  •  go-up   go-down


76. Chang CY, Singal AK, Ganeshan SV, Schiano TD, Lookstein R, Emre S: Use of splenic artery embolization to relieve tense ascites following liver transplantation in a patient with paroxysmal nocturnal hemoglobinuria. Liver Transpl; 2007 Nov;13(11):1532-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrent venous thrombosis following liver transplantation for Budd-Chiari syndrome is common, particularly in the setting of an underlying myeloproliferative disorder.
  • [MeSH-minor] Adult. Anemia, Aplastic / pathology. Female. Humans. Leukemia, Myeloid, Acute / etiology. Liver / pathology. Magnetic Resonance Imaging. Portal Vein / pathology. Thrombosis / etiology. Tomography, X-Ray Computed


77. Manole I, Costăchescu G, Aldea MJ, Gavriluţ M, Dumitraşcu I: [Agnogenic myeloid metaplasia in pregnancy. Case report]. Rev Med Chir Soc Med Nat Iasi; 2010 Apr-Jun;114(2):465-9
Genetic Alliance. consumer health - Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Idiopathic myelofibrosis is a rare myeloproliferative disorder characterized by excessive accumulation of connective tissue in the bone marrow in association with anemia, splenomegaly and extramedullary hematopoiesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20700988.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


78. Baur-Melnyk A, Reiser M: Oncohaematologic disorders affecting the skeleton in the elderly. Radiol Clin North Am; 2008 Jul;46(4):785-98, vii
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic lymphatic leukemia is a typical malignancy of the elderly patient and aplastic anemia is a hematologic disorder characterized by pancytopenia, bone marrow hypoplasia, and lack of extramedullary hematopoiesis.
  • Osteomyelofibrosis and sclerosis are chronic myeloproliferative diseases of the elderly, with a peak incidence in the sixth and seventh decade of life.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18922293.001).
  • [ISSN] 0033-8389
  • [Journal-full-title] Radiologic clinics of North America
  • [ISO-abbreviation] Radiol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Wardrop D, Steensma DP: Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category? Br J Haematol; 2009 Mar;144(6):809-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Given that the provisional classification of RARS-T as a myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndrome, rather than as a form of MPN (i.e., ET), rests principally upon the presence of ring sideroblasts, which are a non-specific morphological finding, these new molecular results prompt reconsideration of the necessity for a distinctive RARS-T category.
  • [MeSH-major] Anemia, Refractory / classification

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19120370.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 9014-42-0 / Thrombopoietin; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 70
  •  go-up   go-down


80. Cokic VP, Beleslin-Cokic BB, Tomic M, Stojilkovic SS, Noguchi CT, Schechter AN: Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood; 2006 Jul 1;108(1):184-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hydroxyurea is a cell-cycle-specific drug that has been used to treat myeloproliferative diseases and sickle cell anemia.
  • These studies established an additional mechanism by which rapid and sustained effects of hydroxyurea may affect cellular NO levels and perhaps enhance the effect of NO in myeloproliferative diseases.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527893.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androstadienes; 0 / Chromones; 0 / Isoquinolines; 0 / Morpholines; 0 / Sulfonamides; 127243-85-0 / N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 31C4KY9ESH / Nitric Oxide; E0399OZS9N / Cyclic AMP; EC 1.14.13.39 / Nitric Oxide Synthase; H2D2X058MU / Cyclic GMP; SY7Q814VUP / Calcium; X6Q56QN5QC / Hydroxyurea; XVA4O219QW / wortmannin
  •  go-up   go-down


81. Friedrisch JR, Prá D, Maluf SW, Bittar CM, Mergener M, Pollo T, Kayser M, da Silva MA, Henriques JA, da Rocha Silla LM: DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea. Mutat Res; 2008 Jan 8;649(1-2):213-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although HU has been associated with an increased risk of leukemia in some patients with myeloproliferative disorders, the mutagenic and carcinogenic potential of HU has not been established.
  • [MeSH-major] Anemia, Sickle Cell / drug therapy. DNA Damage. Hydroxyurea / adverse effects. Leukocytes / drug effects

  • Genetic Alliance. consumer health - Sickle Cell Disease.
  • MedlinePlus Health Information. consumer health - Sickle Cell Anemia.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988936.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antisickling Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


82. Boruchov AM: Thrombocytopenia in myelodysplastic syndromes and myelofibrosis. Semin Hematol; 2009 Jan;46(1 Suppl 2):S37-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary myelofibrosis (MF) is a chronic myeloproliferative disorder associated with hepatosplenomegaly and refractory cytopenias.
  • Immunomodulatory agents have shown promise in treating the anemia associated with this MF.


83. Colagrande M, Di Ianni M, Coletti G, Peris K, Fargnoli MC, Moretti L, Lapecorella M, Tabilio A: Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy. Int J Hematol; 2009 Jan;89(1):76-9
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm characterized by progressive anemia, massive splenomegaly, leukoerythroblastosis, extramedullary hematopoiesis and in about 50% of cases the presence of JAK2V617F mutation.

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19052692.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


84. Kim WI, Matise I, Diers MD, Largaespada DA: RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia. Blood; 2009 Jan 29;113(5):1086-96
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After marked decrease of AML blast cells, myeloproliferative disease (MPD)-like AML relapsed characterized by cells that did not express NRAS(G12V).
  • Moreover, NRAS(G12V) oncogene has a cell nonautonomous role in suppressing erythropoiesis that results in the MPD-like AML show significantly reduced ability to induce anemia.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Genet Metab. 2006 Jul;88(3):216-24 [16678459.001]
  • [Cites] Int J Hematol. 2005 Jul;82(1):9-20 [16105754.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4392s-4395s [16857816.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Aug;3(8):448-57 [16894390.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2349-57 [16763213.001]
  • [Cites] Dev Cell. 2006 Dec;11(6):752-4 [17141149.001]
  • [Cites] Cell Cycle. 2006 Dec;5(24):2878-80 [17218790.001]
  • [Cites] Curr Opin Hematol. 2007 Mar;14(2):85-9 [17255784.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3291-310 [17496923.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5238-41 [17317860.001]
  • [Cites] Nat Rev Drug Discov. 2007 Jul;6(7):541-55 [17585331.001]
  • [Cites] Exp Hematol. 2007 Aug;35(8):1231-9 [17560009.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11657-67 [18089795.001]
  • [Cites] Leukemia. 2008 Jan;22(1):66-77 [17851551.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2329-38 [18056843.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2232-40 [16281072.001]
  • [Cites] Nat Genet. 2000 Jan;24(1):57-60 [10615128.001]
  • [Cites] Mol Membr Biol. 2000 Apr-Jun;17(2):65-73 [10989457.001]
  • [Cites] Cell Mol Life Sci. 2000 Dec;57(13-14):1950-63 [11215520.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5695-707 [11607819.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):282-7 [12042701.001]
  • [Cites] Blood. 2002 Jul 1;100(1):238-45 [12070033.001]
  • [Cites] Science. 2002 Jul 5;297(5578):63-4 [12098689.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):433-43 [12124173.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:179-98 [12194988.001]
  • [Cites] Blood. 2002 Dec 1;100(12):4185-92 [12393454.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3229-35 [12515728.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8671-6 [14647461.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):597-602 [14699048.001]
  • [Cites] J Clin Invest. 2004 Feb;113(4):528-38 [14966562.001]
  • [Cites] Cell Cycle. 2004 May;3(5):536-7 [15020845.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(16):6993-7002 [15282300.001]
  • [Cites] Exp Hematol. 2004 Sep;32(9):852-60 [15345287.001]
  • [Cites] Cell. 1995 Feb 24;80(4):533-41 [7867061.001]
  • [Cites] Cell. 1996 Jun 14;85(6):853-61 [8681380.001]
  • [Cites] Environ Health Perspect. 1996 Dec;104 Suppl 6:1239-46 [9118899.001]
  • [Cites] Leukemia. 1998 May;12(5):792-800 [9593283.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11863-8 [9751756.001]
  • [Cites] Blood. 1999 Mar 15;93(6):2043-56 [10068678.001]
  • [Cites] EMBO J. 1999 Jul 1;18(13):3564-74 [10393173.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):535-8 [15607957.001]
  • [Cites] Semin Cancer Biol. 2005 Jun;15(3):175-88 [15826832.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1054-62 [15831708.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1368-76 [16761017.001]
  • (PMID = 18952898.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA084221; United States / NCI NIH HHS / CA / U01 CA84221
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mllt3 protein, mouse; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ PMC2635074
  •  go-up   go-down


85. Agool A, Schot BW, Jager PL, Vellenga E: 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nucl Med; 2006 Oct;47(10):1592-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Clinical and laboratory data of 18 patients with myelodysplasia (MDS), chronic myeloproliferative disorders, myelofibrosis, aplastic anemia, or multiple myeloma were correlated with the results of 18F-FLT PET using visual analysis and the standardized uptake value (SUV).
  • RESULTS: With SUV and visual analysis, a distinction could be made between MDS (n = 9), chronic myeloproliferative disorders (n = 3), and myelofibrosis (n = 3) compared with healthy control subjects.
  • A significant increase in 18F-FLT uptake was observed in all of the studied patients with MDS and myeloproliferative disorders.
  • In contrast, patients with myelofibrosis and aplastic anemia (n = 1) demonstrated a decline in bone marrow 18F-FLT uptake compared with healthy control subjects.

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17015893.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dideoxynucleosides; 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; PG53R0DWDQ / alovudine
  •  go-up   go-down


86. Wulfert M, Küpper AC, Tapprich C, Bottomley SS, Bowen D, Germing U, Haas R, Gattermann N: Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp Hematol; 2008 May;36(5):577-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Analysis included 104 patients with MDS (24 refractory anemia, 32 refractory anemia with ringed sideroblasts, 34 refractory anemia with excess of blasts, 7 refractory anemia with excess of blasts in transformation to acute leukemia, and 7 chronic myelo-monocytic leukemia), 3 patients with acute myeloid leukemia from MDS, and 36 patients with myeloproliferative disease (23 chronic myeloid leukemia, 9 polycythemia vera, 4 idiopathic myelofibrosis).
  • RESULTS: Heteroplasmic mtDNA mutations, mostly transitions, were identified in 56% of MDS and 44% of myeloproliferative disorders patients.

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439489.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  •  go-up   go-down


87. Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E, Pieri L, Pancrazzi A, Ponziani V, Delaini F, Longo G, Ammatuna E, Liso V, Bosi A, Barbui T, Vannucchi AM: Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood; 2009 Aug 20;114(8):1477-83
Hazardous Substances Data Bank. L-Valine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 186 patients with primary myelofibrosis (PMF) were genotyped for JAK2V617F at diagnosis aimed at analyzing the correlation of mutational status and mutated allele burden with outcome variables, including time to anemia, leukocytosis, leukopenia, thrombocytopenia, massive splenomegaly, leukemia, and with overall survival.
  • Patients in the lower quartile had shorter time to anemia and leukopenia and did not progress to large splenomegaly.
  • We conclude that a low JAK2V617F allele burden at diagnosis is preferentially associated with a myelodepletive rather than myeloproliferative phenotype and represents an independent factor associated with shortened survival in patients with PMF.

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549988.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 47E5O17Y3R / Phenylalanine; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; HG18B9YRS7 / Valine
  •  go-up   go-down


88. Srivastava AS, Malhotra R, Esmaeli-Azad B, Lane T, Carrier E: Prospects of embryonic stem cells in treatment of hematopoietic disorders. Curr Pharm Biotechnol; 2007 Oct;8(5):305-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrances in this intricate process may lead to a malignancy of essential blood-forming organs, causing diseases such as leukemia, aplastic anemia, lymphoma, myelodysplasia and myeloproliferative disorders.

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979728.001).
  • [ISSN] 1873-4316
  • [Journal-full-title] Current pharmaceutical biotechnology
  • [ISO-abbreviation] Curr Pharm Biotechnol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 187
  •  go-up   go-down


89. Awasthi A, Das R, Varma N, Ahluwalia J, Gupta A, Marwaha RK, Garewal G: Hematological disorders in Down syndrome: ten-year experience at a Tertiary Care Centre in North India. Pediatr Hematol Oncol; 2005 Sep;22(6):507-12
MedlinePlus Health Information. consumer health - Down Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These comprised 4 cases of transient myeloproliferative disorder (TMD), 3 cases of TMD/acute leukemia, 4 cases of acute leukemia (AL), 2 of dual deficiency anemia, and 1 case each of myelofibrosis and idiopathic thrombocytopenia.

  • Genetic Alliance. consumer health - Down Syndrome.
  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169817.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


90. Barosi G, Hoffman R: Idiopathic myelofibrosis. Semin Hematol; 2005 Oct;42(4):248-58
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Idiopathic myelofibrosis (IMF) is characterized by anemia, progressive splenomegaly, bone marrow fibrosis, and extramedullary hematopoiesis.
  • However, patients with a transitional myeloproliferative disorder (MPD), a prefibrotic form of myelofibrosis, or myelofibrosis with a fatty bone marrow share many features of IMF but have clinical characteristics that deviate from the classical description of IMF.
  • Androgens, recombinant human erythropoietin (rHuEpo), and thalidomide are effective modalities of treatment of the anemia of IMF.

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16210038.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 104
  •  go-up   go-down


91. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med; 2010 Sep 16;363(12):1117-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Myelofibrosis is a Philadelphia chromosome–negative myeloproliferative neoplasm associated with cytopenias, splenomegaly, poor quality of life, and shortened survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia / drug therapy. Anemia / etiology. Biomarkers / blood. Cytokines / blood. Dose-Response Relationship, Drug. Female. Hepatomegaly / drug therapy. Hepatomegaly / etiology. Humans. Male. Middle Aged. Mutation. STAT3 Transcription Factor / drug effects. STAT3 Transcription Factor / metabolism. Spleen / drug effects. Spleen / pathology

  • Genetic Alliance. consumer health - Myelofibrosis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] N Engl J Med. 2010 Sep 16;363(12):1180-2 [20843255.001]
  • [CommentIn] N Engl J Med. 2010 Dec 16;363(25):2464; author reply 2464-5; discussion 2465 [21158663.001]
  • [Cites] Leukemia. 2008 May;22(5):905-14 [18385755.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4030-6 [17712047.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1013-8 [8704209.001]
  • [Cites] Cancer. 2007 Jan 1;109(1):68-76 [17123268.001]
  • [Cites] Cancer. 2001 Sep 15;92(6 Suppl):1684-8 [11598887.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):709-15 [16115126.001]
  • [Cites] Am J Med. 2004 Nov 15;117(10):755-61 [15541325.001]
  • [Cites] Blood. 2009 Mar 26;113(13):2895-901 [18988864.001]
  • [Cites] Exp Hematol. 2007 Nov;35(11):1641-6 [17920755.001]
  • [Cites] Curr Opin Hematol. 2006 Mar;13(2):87-92 [16456374.001]
  • [Cites] Blood. 2010 Apr 15;115(15):3109-17 [20130243.001]
  • [Cites] Br J Haematol. 2005 Nov;131(3):320-8 [16225651.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2009;:636-42 [20008249.001]
  • [Cites] N Engl J Med. 2000 Apr 27;342(17):1255-65 [10781623.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1497-503 [16675707.001]
  • [Cites] Leukemia. 2008 Apr;22(4):756-61 [18216871.001]
  • [Cites] J Physiol Pharmacol. 2008 Dec;59 Suppl 9:251-64 [19261984.001]
  • [Cites] Blood. 2009 Aug 20;114(8):1477-83 [19549988.001]
  • [Cites] Leuk Res. 2009 Sep;33(9):1199-203 [19250674.001]
  • (PMID = 20843246.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00509899
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytokines; 0 / INCB018424; 0 / Pyrazoles; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; EC 2.7.10.2 / Janus Kinase 1; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


92. Gong XB, Lu XG, Xu GB, Wu XG, Wang L, Zhang XH, Zhu L, Wang WQ: [Value of imprint in bone marrow morphological examination]. Zhonghua Yi Xue Za Zhi; 2010 Jun 8;90(22):1531-6
MedlinePlus Health Information. consumer health - Blood Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In BM imprint group, the diagnostic accuracy for hypersplenism (n = 130), metastatic carcinoma (n = 67), refractory anemia with excess blasts, myeloproliferative neoplasm (n = 174), and PCM (n = 94) were better than smear group (96.9% vs 80.7%, 91.0% vs 76.1%, 92.6% vs 81.5%, 92.5% vs 76.4%, and 97.8% vs 92.6% respectively, all P < 0.05); And the diagnostic accuracy for megaloblastic anemia (n = 69), acute myeloid leukemia (n = 104), refractory cytopenia with unilineage dysplasia (n = 15), refractory cytopenia with multilineage dysplasia (n = 22), and lymphoplasmacytic lymphoma (n = 12) were higher than biopsy section group (100% vs 84.0%, 91.3% vs 74.0%, 86.7% vs 60.0%, 90.
  • 9% vs 72.7%, and 66.6% vs 50.0% respectively, all P < 0.05); And the diagnostic accuracy for myelodysplastic/myeloproliferative neoplasm (n = 26) was higher than smear group (76.3%, P < 0.05) and biopsy section group (78.2%, P < 0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973233.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


93. Bousquet M, Harris MH, Zhou B, Lodish HF: MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci U S A; 2010 Dec 14;107(50):21558-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All mice transplanted with fetal liver cells ectopically expressing miR-125b showed an increase in white blood cell count, in particular in neutrophils and monocytes, associated with a macrocytic anemia.
  • Among these mice, half died of B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, or a myeloproliferative neoplasm, suggesting an important role for miR-125b in early hematopoiesis.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Dec 1;102(12):3938-46 [12907435.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13137-42 [8917557.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3829-40 [9808576.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 May;6(5):376-85 [15852042.001]
  • [Cites] Leukemia. 2005 Nov;19(11):2009-10 [16151463.001]
  • [Cites] Cell. 2005 Dec 2;123(5):819-31 [16325577.001]
  • [Cites] Cell. 2007 Apr 6;129(1):147-61 [17382377.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 24;104(17):7080-5 [17438277.001]
  • [Cites] Nat Cell Biol. 2007 Jul;9(7):775-87 [17589498.001]
  • [Cites] Cell. 2007 Oct 5;131(1):146-59 [17923094.001]
  • [Cites] Nature. 2008 Feb 28;451(7182):1125-9 [18278031.001]
  • [Cites] J Exp Med. 2008 Mar 17;205(3):585-94 [18299402.001]
  • [Cites] J Exp Med. 2008 Oct 27;205(11):2499-506 [18936236.001]
  • [Cites] Genes Dev. 2009 Apr 1;23(7):862-76 [19293287.001]
  • [Cites] Cell Physiol Biochem. 2009;23(4-6):347-58 [19471102.001]
  • [Cites] PLoS One. 2009;4(11):e7826 [19915715.001]
  • [Cites] Genes Dev. 2009 Dec 15;23(24):2806-11 [20008931.001]
  • [Cites] Leukemia. 2010 Jan;24(1):89-96 [19890372.001]
  • [Cites] Cancer Cell. 2010 Jan 19;17(1):28-40 [20060366.001]
  • [Cites] Genes Dev. 2010 Mar 1;24(5):478-90 [20194440.001]
  • [Cites] J Biol Chem. 2010 Jul 9;285(28):21496-507 [20460378.001]
  • [Cites] Leukemia. 2010 Jul;24(7):1362-4 [20485370.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14229-34 [20616003.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14235-40 [20660734.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1144-50 [10666183.001]
  • [Cites] Leukemia. 2003 Apr;17(4):807-10 [12682644.001]
  • (PMID = 21118985.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK068348; United States / NIDDK NIH HHS / DK / R56 DK068348; United States / NIDDK NIH HHS / DK / R01 DK068348; United States / NHLBI NIH HHS / HL / 5P01 HL066105; United States / NHLBI NIH HHS / HL / P01 HL066105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MIRN125 microRNA, human; 0 / MicroRNAs; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Other-IDs] NLM/ PMC3003065
  •  go-up   go-down


94. Mesa RA, Tefferi A: Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs; 2009 Sep;14(3):471-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The discovery of the JAK2-V617F mutation, and other pathogenetic insights into the pathophysiology of myeloproliferative neoplasms, has ushered in an era of potential new therapies for MF.
  • Parallel trials with immunomodulatory therapy for MF associated anemia and stromal manifestations of the disease are continuing.

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • Genetic Alliance. consumer health - Myelofibrosis.
  • Genetic Alliance. consumer health - Polycythemia vera.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19552608.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 53
  •  go-up   go-down


95. Mesa RA, Tefferi A, Lasho TS, Loegering D, McClure RF, Powell HL, Dai NT, Steensma DP, Kaufmann SH: Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. Leukemia; 2006 Oct;20(10):1800-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apoptosis was lower in MMM neutrophils (median 41% apoptotic cells, n=50) compared to controls (median 66%, n=9) or other myeloproliferative disorder patients (median 53%, n=11; P=0.002).
  • Apoptotic resistance in MMM correlated with anemia (P=0.01) and the JAK2-V617F (P=0.01).

  • Genetic Alliance. consumer health - Myelofibrosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871275.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA96780; United States / NCI NIH HHS / CA / R01 CA69008
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


96. Mesa RA: Assessing new therapies and their overall impact in myelofibrosis. Hematology Am Soc Hematol Educ Program; 2010;2010:115-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical management of myelofibrosis (MF)--whether primary or arising from an antecedent myeloproliferative neoplasm (post-essential thrombocythemia/polycythemia vera MF)--is currently in a period of transition that began with the discovery of the JAK2-V617F mutation 5 years ago.
  • However, the JAK2 inhibitors can cause anemia and/or gastrointestinal disturbance, and their impact on JAK2 allele burden and the natural history is not yet fully defined.
  • Several additional therapies that do not directly target JAK2 (eg, immunomodulatory drugs, histone deacetylase inhibitors, and inhibitors of the mammalian target of rapamycin [mTOR]) may ameliorate MF-associated anemia and morbidity-inducing symptoms.

  • Genetic Alliance. consumer health - Myelofibrosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21239780.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors
  •  go-up   go-down


97. Carmichael CL, Majewski IJ, Alexander WS, Metcalf D, Hilton DJ, Hewitt CA, Scott HS: Hematopoietic defects in the Ts1Cje mouse model of Down syndrome. Blood; 2009 Feb 26;113(9):1929-37
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Down syndrome (DS) persons are born with various hematopoietic abnormalities, ranging from relatively benign, such as neutrophilia and macrocytosis, to a more severe transient myeloproliferative disorder (TMD).
  • Our analyses identified defects in mature blood cells, including macrocytosis and anemia, as well as abnormalities in fetal liver and bone marrow stem and progenitor cell function.


98. Chen Z, Chen SJ, Zhou GB: [Experimental hematology bridging the gap between laboratory and clinic: hope of hematology]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb;16(1):1-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dissection of disease pathogenesis not only elucidates molecular basis of disorders including hemoglobinopathy, aplastic anemia, hemophilia, hematopoietic malignancies such as leukemia and myeloproliferative disorders, but also provides therapeutic targets for drug development.

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • MedlinePlus Health Information. consumer health - Laboratory Tests.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18315892.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Editorial; English Abstract
  • [Publication-country] China
  •  go-up   go-down


99. Wicke DC, Meyer J, Buesche G, Heckl D, Kreipe H, Li Z, Welte KH, Ballmaier M, Baum C, Modlich U: Gene therapy of MPL deficiency: challenging balance between leukemia and pancytopenia. Mol Ther; 2010 Feb;18(2):343-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inherited loss-of-function mutations of MPL cause severe thrombocytopenia and aplastic anemia, a syndrome called congenital amegakaryocytic thrombocytopenia (CAMT).
  • Treated mice developed a profound yet transient elevation of multilineage hematopoiesis, which showed morphologic features of a chronic myeloproliferative disorder (CMPD) with progressive pancytopenia.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene Ther. 2007 Mar;14(5):415-28 [17051251.001]
  • [Cites] PLoS Med. 2006 Jul;3(7):e270 [16834459.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5186-90 [17347409.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jun;1106:152-74 [17468237.001]
  • [Cites] Mol Ther. 2008 Mar;16(3):525-33 [18195719.001]
  • [Cites] Mol Ther. 2008 Apr;16(4):718-25 [18334985.001]
  • [Cites] Cell Stem Cell. 2007 Dec 13;1(6):671-84 [18371408.001]
  • [Cites] Cell Stem Cell. 2007 Dec 13;1(6):685-97 [18371409.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1519-28 [18496560.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1778-85 [18796624.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1768-77 [18845793.001]
  • [Cites] Mol Ther. 2009 Apr;17(4):716-24 [19240697.001]
  • [Cites] J Clin Invest. 2009 Apr;119(4):964-75 [19307726.001]
  • [Cites] Mol Ther. 2009 Jun;17(6):1073-82 [19259069.001]
  • [Cites] Stem Cells Dev. 2009 Sep;18(7):1081-92 [19025339.001]
  • [Cites] Mol Ther. 2007 Mar;15(3):445-56 [17228317.001]
  • [Cites] Mol Ther. 2000 Nov;2(5):435-45 [11082317.001]
  • [Cites] Blood. 2001 Jan 1;97(1):139-46 [11133753.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2664-72 [11675336.001]
  • [Cites] Science. 2002 Apr 19;296(5567):497 [11964471.001]
  • [Cites] Blood. 2002 Aug 1;100(3):1072-4 [12130527.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2026-31 [12200362.001]
  • [Cites] Exp Hematol. 2003 Dec;31(12):1206-14 [14662326.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2281-90 [15198957.001]
  • [Cites] Virology. 1986 Mar;149(2):242-6 [3004028.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Feb;87(4):1332-6 [2304901.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1990 Summer;12(2):225-30 [2378417.001]
  • [Cites] Cell. 1990 Dec 21;63(6):1137-47 [2175677.001]
  • [Cites] J Virol. 1991 Jan;65(1):464-7 [1985210.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5640-4 [1608974.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):4979-82 [7534285.001]
  • [Cites] J Clin Invest. 1995 Sep;96(3):1683-7 [7657840.001]
  • [Cites] Blood. 1996 Jan 15;87(2):567-73 [8555478.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2154-61 [8630374.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2162-70 [8630375.001]
  • [Cites] Blood. 1996 Sep 1;88(5):1656-65 [8781421.001]
  • [Cites] Blood. 1997 May 15;89(10):3544-53 [9160659.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1195-200 [9448308.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1901-8 [9490672.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8093-7 [9653145.001]
  • [Cites] J Virol. 1999 May;73(5):4083-9 [10196304.001]
  • [Cites] Exp Hematol. 1999 Sep;27(9):1409-17 [10480432.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4235-46 [15713797.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3339-47 [16322778.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):636-44 [16351641.001]
  • [Cites] Mol Ther. 2006 Feb;13(2):391-400 [16226060.001]
  • [Cites] Br J Haematol. 2006 Sep;134(5):453-66 [16856888.001]
  • [Cites] Gene Ther. 2006 Nov;13(21):1524-33 [16763662.001]
  • [ErratumIn] Mol Ther. 2010 Feb;18(2):448
  • (PMID = 19844195.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Thrombopoietin; EC 2.7.2.3 / Phosphoglycerate Kinase
  • [Other-IDs] NLM/ PMC2839299
  •  go-up   go-down


100. Tsai WH, Lee YM, Ing-Tiau Kuo B, Ho CK, Liao PT, Liu MD, Kou YR, Hsu HC: Increased seroprevalence of human herpesvirus 8 in patients with hematological disorders. Acta Haematol; 2005;114(2):95-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A significantly higher seropositive rate can be found in patients with lymphoma, leukemia, autoimmune cytopenias and myeloproliferative disorders, but not in patients with myeloma or aplastic anemia.

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16103632.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Immunoglobulin G
  •  go-up   go-down






Advertisement